Cardium Therapeutics - Der Countdown läuft - 500 Beiträge pro Seite

[Der.Eroberer]

Sehr interessanter Wert mit einer realistischen Chance auf Vervielfachung,
nach erfolgter Zulassung von Excellagen furch die FDA.

Marketcap: 30 Mio $
Cash: 10 Mio $
Aktueller Kurs: $ 0,40

Anfang Dezember 2009 wurden der FDA die Daten von Excellagen in Form einer
510(k) zur Prüfung vorgelegt.
Üblicherweise entscheidet die FDA innerhalb von 90-180 Tagen über eine Zulassung.
Hier wartet man nun seit knapp 9 Monaten auf eine Entscheidung. Es
wäre wichtig zu erwähnen, dass die FDA nicht verpflichtet ist innerhalb
der 180 Tage-Frist zu antworten. Somit ist der Zeitpunkt der Entscheidung
offen und kann jederzeit veröffentlicht werden. Mit jedem zusätzlichen
Tag steigt die Wahrscheinlichkeit einer Entscheiung durch die FDA.
Jedoch ist diese Unsicherheit bezüglich des Zeitpunkts der Entscheidung
auch der Knackpunkt dieser Spekulation. Viele Trader haben nach dem
Ablauf der 180 Tage ihre Anteile abgegeben, um sich auf abschätzbarere
Werte zu konzentrieren. Deshalb steht Cardium auch nicht weit über dem
52-Wochen-Tief.

Excellagen ist ein Wundheilungspräparat, dass in Gelform aufgetragen wird.
Die Studienergebnisse haben eine bis 30% schnellere Wundheilung als
bei der gegenwärtigen Standardanwendung (Regranex Gel) aufgezeigt.
Der Markt für die Anwendung an Fußgeschwüren von Diabetikern wird auf bis zu
2 Mrd Dollar geschätzt. Entsprechend groß ist das Potenzial dieser kleinen Firma.
Nach erfolgter Zulassung wird Excellagen wohl auslizensiert und könnte
schätzungsweise alleine 300 Mio an Upfront Payments einbringen. Wohlgemerkt
ist CXM mit 30 Mio Dollar bewertet. Wie stichhaltig diese Schätzungen allerdings sind
überlasse ich jedem einzelnen selbst zu beurteilen.

Was passiert, wenn eine unerwartete Zulassung kommt, konnte man schön bei BSDM
verfolgen. Dawson Jams Sec. hat ein Kursziel von
$ 1,50 für CXM abgegeben. Das halte ich bei erfolgter Zulassung für sehr konservativ.

Keine Kauf- oder Verkaufsempfehlung

[Ahorne]

Antwort auf Beitrag Nr.: 40.049.188 von Der.Eroberer am 26.08.10 13:33:23

Hallo Der.Eroberer

Klingt nach einen spannenden Zock.

Werde mir Cardium mal genauer anschauen.

cu

[Ahorne]

Antwort auf Beitrag Nr.: 40.049.354 von Ahorne am 26.08.10 13:55:25

Hompepage:
http://www.cardiumthx.com/#

Cardium Reports on Second Quarter 2010 Financial Results and Recent Developments
http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-new…

Gibt eine Tendenz wie sich die FDA Entscheiden könnte?

cu

[Der.Eroberer]

Ein Präparat vor der Zulassung und ein weiterer Wirkstoff (Generx) demnächst in Phase III.
Und beides erhält man für 30 Mio $. Der Markt neigt manchmal dazu Perlen zu übersehen.

Das Sicherheitsprofil und die Wirksamkeit von Excellagen sind ansprechend. Aber die FDA
ist dennoch unberechenbar. Es ist einen "Zock" wert und nach erfolgter Zulassung wird CXM ihren Weg
machen.

Habe heute bei Kursen um 0,40 $ nochmals nachgelegt und warte nun auf die kommenden
Nachrichten. Mit einer BSDM vor Augen, kommt leichter Nervenkitzel auf.

[Der.Eroberer]

Netter Schlusskurs gestern...

Eine Analyse zu CXM:

http://www.dawsonjames.com/portal/CXM_Initiation_4_20_2010.p…

[Ahorne]

Antwort auf Beitrag Nr.: 40.053.805 von Der.Eroberer am 27.08.10 09:12:12

Diese Produkte "MedPodium" sollten in den nächsten Monate lanciert werden:
http://www.cardiumthx.com/pdf/MedPodium-Brochure.pdf

Cardium Announces Dominique Dawes, Olympic Champion, as Web-Based Spokesperson for New MedPodium Podiatry-Focused Advanced Skin Care Product Line
http://www.prnewswire.com/news-releases/cardium-announces-do…

[Der.Eroberer]

Schöne Darstellung der Sachlage:

http://en_ca.www.smallcapnetwork.com/Cardium-Therapeutics-wa…

[Ahorne]

Antwort auf Beitrag Nr.: 40.069.854 von Der.Eroberer am 30.08.10 20:02:31

Hallo Eroberer, danke für den Thread. Ich bin jetzt auch CXM Aktionär.

Cardium Therapeutics (NYSE AMEX: CXM): Pioneering a New Hybrid Business Model for Biotechnology
By Justin Kuepper on Thursday, August 26th, 2010
http://biotechstocktrader.com/cardium-therapeutics-nyse-amex…

Intressanter Bericht über die Strategie der Firma

ein Auszug:
During our interview, Cardium reported that it has reviewed over twenty product, technology and business opportunities during the past six months. They remain very selective because, as we all know, finding a diamond in the rough is never easy. At the same time they are excitedly advancing forward on their current capital-efficient medical opportunities portfolio.

[Ahorne]

Antwort auf Beitrag Nr.: 40.052.266 von Der.Eroberer am 26.08.10 20:57:05

Nervenkitzel... jetzt weiss ich was Du meinst Explosive Sache

http://www.bilder-hosting.de/img/RD4E5.gif

cu

[Ahorne]

Antwort auf Beitrag Nr.: 40.076.729 von Ahorne am 31.08.10 18:57:31

so jetzt sollte es klappen:

[Der.Eroberer]

Antwort auf Beitrag Nr.: 40.077.189 von Ahorne am 31.08.10 20:06:00

BSDM ist auch mein Vorbild für diesen Zock. Eines ist in jedem Falle klar - wenn die
Zulassung kommt, dann wird der Kurs direkt über 1 Dollar eröffnen. Wieviel über 1 Dollar
mag ich nicht abzuschätzen. CXM birgt enormes Potenzial bei großem Risiko. Das kitzelt
die Nerven...

[Dicker69]

Guten Abend,
wollte mich jetzt auch melden und bin ab sofort CXM Aktionär. Na dann, auf grüne Tage und einen ruhigen und sachlichen Thread.

Gruß Dicker

[Der.Eroberer]

Antwort auf Beitrag Nr.: 40.084.737 von Dicker69 am 01.09.10 20:36:34

Willkommen im erlesenen Kreis!

Und wieder einen Tag dichter an die Zulassung...

[Dicker69]

Antwort auf Beitrag Nr.: 40.085.444 von Der.Eroberer am 01.09.10 22:30:08

Danke,
wir es ja bald wissen ob die Zulassung kommt.Die Frage ist immer noch ,,Wann,,?

Gruss Dicker

[Dicker69]

schon paar Tage alt, aber hoch Intressant.........


(Google-Übersetzung)


Cardium Therapeutics (CXM) tritt in MSA mit bioRASI Zur Unterstützung Ad5FGF-4 Drug Candidate

Cardium Therapeutics (AMEX: CXM ) gab heute bekannt, dass IT-Organisation, eingegangen in ein Master Services Agreement mit bioRASI, einem internationalen Vertrag Forschung (Assist Cardium bei der Durchführung einer geplanten späten Phase der klinischen Studie und Vermarktungsaktivitäten für Cardium Generx Ad5FGF- 4) Medikamentenkandidaten in Russland und der angeschlossenen Ländern, sowie in anderen Schwellenländern potenziell Märkten. Unter den Bedingungen der Vereinbarung wird bioRASI unterstützen Cardium zu einem späten Stadium Verhalten klinischen Studie zur Wirksamkeit und Sicherheit von Cardium Generx Produkt Kandidaten bis zu drei bewerten führenden medizinischen Zentren in Moskau und an das Unternehmen bei der Vermarktung unterstützen die Aktivitäten in diesen internationalen Märkte.

Die Generx klinischen Studie wird voraussichtlich in der zweiten Hälfte dieses Jahres begonnen werden und wird eine randomisierte, kontrollierte, Parallelgruppen-, multizentrische Studie zur Sicherheit und Wirksamkeit von Generx mit Adenosin-SPECT-Bildgebung des myokardialen Blutflusses bei Patienten mit stabiler bewerten Angina pectoris. Der primäre Endpunkt ist die Veränderung in reversible Perfusionsdefekt Größe als durch Adenosin-SPECT-Bildgebung, die direkt vergleichbar, die erfolgreich in einer klinischen Studie der Phase 2a der Generx verwendet gemessen werden.

Positive Ergebnisse aus dem Stand der Phase 2a der klinischen Studie (Grines et al. Zeigten J Am Coll Cardiol 2003; 42:1339-47), dass Generx myokardialen Blutfluss im ischämischen Region die Herzen der Männer und Frauen zu verbessern nach einer einzigen intrakoronare Infusion als durch das Ziel Wirksamkeitsendpunkt der SPECT-Bildgebung gemessen. Wie in der Publikation hingewiesen, beobachtet die mittlere Veränderung in Generx behandelten Patienten war eine absolute Reduktion von 4,2% (das entspricht einer relativen Reduktion um 20%) in der reversiblen Perfusionsdefekt Größe gegenüber dem Ausgangswert in acht Wochen (p <0,001), während die Placebo- Gruppe zeigten nur eine absolute Reduktion um 1,6% gegenüber dem Ausgangswert (nicht signifikant) um acht Wochen nach der Behandlung. Die beobachtete Wirkung der Behandlung bei Patienten, die Generx war ähnlich in Größe, um die in der Literatur für Patienten, die sich einer Angioplastie / Stent oder Revaskularisation mit reversiblen Perfusionsdefekten von vergleichbarer Größe in einem Jahr nach dieser Verfahren berichtet.

Das Unternehmen ist überzeugt, dass Generx könnte als eine kostengünstige Front-Line-Therapie für Patienten mit koronarer Herzkrankheit in den großen Märkten in Schwellenländern, die häufig keinen Zugang zu teuren Advanced Care Verfahren wie koronare Angioplastie und Stent entwickelt werden, oder Herz-Bypass-Operationen (die in den USA können $ 50.000 bis $ 100.000 über einen Zeitraum von fünf Jahren Kosten folgenden Erstbehandlung). Nachdem diese zusätzliche klinische Beweise zur Bestätigung der Sicherheit und Wirksamkeit von Generx zur Verbesserung der koronaren Kollateralen bei Männern und Frauen mit schwerer koronarer Herzkrankheit Zudem könnte verwendet werden, um zu optimieren und zu erweitern kommerzielle Entwicklung Signalwege in den USA und anderen wichtigen Märkten wie Europa sein.

"Wir sind mit bioRASI wie ihre expansiven globalen klinischen Forschung Erfahrung arbeiten sollte Cardium mit einer effektiven und kostengünstigen Mittel zur Förderung unserer Generx Produktentwicklung Bemühungen stellen und die Erweiterung unserer klinischen Datenbank, um die potenzielle Vermarktung dieser neuartigen Produktkandidaten Unterstützung freuen. Basierend auf den Daten hervorgeht, dass zu Generx scheint sicher und hat das Potential, wesentlich erhöhen koronaren Blutfluss im Rahmen von Herzerkrankungen, zusammen mit einer unabhängigen 10-Jahres-Studie, dass die Bedeutung der koronaren Zirkulation für die langfristige Gesundheit des Herzens unterstrichen, glauben wir, dass unser Produkt Generx Kandidat könnte als Front-Line-Therapie bei koronarer Herzkrankheit von einer globaleren Perspektive entwickelt werden. Zusätzliche gewonnenen Daten aus unserer geplanten klinischen Studie soll auch helfen, die Unterstützung eines erweiterten US Registrierungsunterlagen durch zusätzliche Daten zur Sicherheit und Wirksamkeit möglicherweise alternative Maßnahmen. Je mehr objektive SPECT-Endpunkt soll direkt bewerten die Fähigkeit des Herzens, myokardialen Blutflusses unter Bedingungen wie Stress erhöhen und gilt als ein wichtiger Indikator für die kardiale Funktion und die Fähigkeit eines Patienten, das Herz effektiv handhaben Routine Bewegung und täglichen Aktivitäten, die einen dramatischen Einfluss auf die Gesundheit eines Patienten und die Lebensqualität haben kann ", sagte Christopher J. Reinhard, Cardium Chairman und Chief Executive Officer

http://translate.google.de/translate?hl=de&sl=en&tl=de&u=htt…

[Dicker69]

grüner Tagesabschluß

Wünsche eine gute N8
Dicker

[Der.Eroberer]

Hier brodelt es gewaltig. Es geht von Tag zu Tag ein Stückchen höher. Niemand weiß
wann die Entscheidung kommt und deshalb sollte man schleunigst auf den Zug aufspringen.

[Ahorne]

Antwort auf Beitrag Nr.: 40.094.848 von Der.Eroberer am 03.09.10 12:31:16

so sehe ich das auch... noch sind wir hier zu 3... doch das in Intresse in Übersee auch noch gering... doch wie Du sagst... das kann sich ändern

cu

[Ahorne]

Antwort auf Beitrag Nr.: 40.094.848 von Der.Eroberer am 03.09.10 12:31:16

ps... bei 0.51 USD wartet die 200 SMA Line... schaun wir mal ob sie bald genackt wird:

http://finance.yahoo.com/echarts?s=CXM+Interactive#chart3:sy…

[Ahorne]

Rodman & Renshaw Annual - Global Investment Conference
12th Annual Healthcare Conference
New York Palace Hotel, NY - 12. - 15. September 2010

http://www.rodmanandrenshaw.com/conferences?id=51&link=prese…

[Dicker69]

Antwort auf Beitrag Nr.: 40.097.941 von Ahorne am 03.09.10 18:59:21

Danke und ob wir vor dem WE noch die 0,48 sehen?

Gruss Dicker

[Ahorne]

Auf Yahoo Finance ist ein bisschen mehr los als hier... Betonung auf ein bisschen
http://messages.finance.yahoo.com/mb/CXM

Anbei ein nettes Posting:

CXM soon on everyone's radar
29-Jun-10 09:35 am

This biotech has all you want:- far too low marketcap
- 1.5 billion market
- almost fda approved product
- buy-out candidate
- european chances
- no debt
- compliance with amex
- enough cash
- few outstanding shares
- all time low --> (na ja... in der Nähe, aber nicht mehr ganz unten)
- oversold chart.

[Ahorne]

Antwort auf Beitrag Nr.: 40.118.522 von Ahorne am 08.09.10 15:12:33

News Release
Cardium Announces Appexium(TM), a New Weight Loss Management Dietary Supplement to Expand MedPodium's Healthy Lifestyle Product Initiative
SAN DIEGO, Sept 09, 2010 /PRNewswire via COMTEX/ --
http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-new…

Cardium Therapeutics (NYSE Amex: CXM) today announced the addition of a new weight management product, Appexium(TM), to Cardium's MedPodium(TM) product line. Appexium, a plant-derived non-prescription dietary supplement to be marketed under the trade name Linee(TM), is designed to manage weight by lowering appetite and hunger in order to reduce caloric intake and facilitate weight loss. Cardium is planning to formally launch its MedPodium product line in October. The addition of Appexium represents an important step toward broadening the Company's advanced skin care line to include additional healthy lifestyle medicinals.


(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

Appexium, taken orally an hour before meals and snacks, is designed to physiologically send a satiety signal to the brain to effectively reduce appetite. Appexium's active ingredient is a highly-concentrated extract from white potato, standardized to Proteinase Inhibitor-II (PI-2), that promotes the release cholecystokinin (CCK), a natural peptide hormone secreted by the small intestine and released into the blood stream. CCK is a well-researched peptide that is believed to play an important role in modulating appetite and hunger. Appexium's custom formulation contains a blend of PI-2, vitamin D and vitamin B-12, which is filled into small, easy swallow, pharmaceutical-quality capsules. Appexium may be used as a stand-alone product, integrated as part of exercise, yoga and other fitness programs, or used in concert with popular weight-loss and dietary meal plan programs to enhance plan compliance and improve results.

"We are pleased to announce the addition of Appexium to our MedPodium lifestyle medicinal brand initiative. Following our planned launch of the MedPodium product platform in October, which will initially include seven podiatry-focused advanced skin care products and Appexium, we plan to further broaden and expand our MedPodium brand initiative to encompass other lifestyle medicinals that may include neurologics, metabolics and aesthetics designed to address emerging lifestyle issues for highly-targeted market segments. Our products will initially be available through Cardium's MedPodium web-based boutique. Following market launch we also plan to market and sell certain products through various select distributors or retailers in the United States," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium.

About Appexium

Appexium is a dietary supplement based on the use of Proteinase Inhibitor-II (PI-2), a naturally-occurring protein derived from white potato that is a commonly consumed food and generally recognized as safe. While extracted and concentrated, PI-2 is not altered chemically. It is designed to physiologically send a satiety signal to the brain in order to reduce appetite and hunger. Its mechanism of action does not rely on absorbing fat or causing fullness or bloating in the gastrointestinal (GI) tract as in many other weight loss aids and dietary supplements that are sometimes not well tolerated due to discomfort, GI bloating and irregular bowel discharge. Based on independent clinical studies, Appexium's active ingredient promotes the release of clinically meaningful levels of cholecystokinin (CCK) that may increase feelings of fullness and therefore help to reduce the amount of food eaten daily.(1)(2) While exercise is important, years of research has suggested that the most effective means of ensuring weight loss in the average healthy person is by reducing total daily caloric intake. The CCK satiety mechanism of action has been well researched. Based on a multi-site, randomized, double-blind, controlled clinical study, patients receiving the PI-2 active ingredient, twice daily before the two largest meals, had statistically significant reductions in overall weight as well as in waist and hip measurements, as compared to placebo.(3)

About MedPodium

The MedPodium product line initially included seven podiatry-focused advanced skin care products designed to promote health and comfort and support preventative care, self examination and early detection of foot ulcers, especially for diabetic patients with lower extremity neuropathy. The MedPodium podiatry-focused skin care products have been formulated to include blended natural and botanical ingredients, and have no artificial colors and fragrances. The various products contain exfoliants to promote the release of dead skin cells and stimulate the production of new skin cells, natural vitamin antioxidants, as well as other nutrient-rich elements to promote soft, supple and healthy skin. The addition of Appexium further broadens and expands Cardium's in-house MedPodium brand initiative to encompass other healthy lifestyle medicinals.

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium lifestyle medicinals brand platform. The Company's lead product candidates include: (1) Excellagen(TM) topical gel, for wound care management, which Cardium plans to market launch in the fourth quarter subject to pending FDA 510(k) clearance; and (2) Generx(R), a DNA-based angiogenic cardiovascular biologic for patients in international markets with coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that the MedPodium product platform will be commercially successful or will effectively enhance our businesses or their market value, that the MedPodium product line can be successfully broadened to include additional healthy lifestyle opportunities, that Appexium or our other products will prove to be sufficiently safe and effective after introduction into a broader patient population, that the FTC will accept the clinical studies cited in this release as substantiation for the product claims; that results or trends observed in clinical studies or other observations will be reproduced in subsequent studies or in broader use, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that FDA or other health regulatory agencies will not introduce additional or more restrictive regulations covering naturally-derived products such as those in our MedPodium product line, that our in-house or external product commercialization efforts will be successful or will effectively enhance our businesses or their market value, or that any of the third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of biologics and in the conduct of human clinical trials and other product development efforts, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition and regulation, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.


Badman, MK, Flier, JS. The Gut and Energy Balance: Visceral Allies in the Obesity Wars. (2005) Science. 307: 1909-1914
Hu, J, Edmonson B, Radosevich J. The effectiveness of potato proteinase inhibitor II in promoting satiety in healthy human subjects: VAS summary. Kemin Consumer Care White Paper. 2004
Dana, S. A randomized, double-blind, placebo-controlled clinical study demonstrates Slendesta potato extract is a safe and effective tool for promoting weight reduction. Kemin Consumer Literature

Note: The statements in this press release have not been evaluated by the Food and Drug Administration. Appexium is not intended to diagnose, treat, cure or prevent any disease.

Copyright 2010 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics(TM) Generx(R) and MedPodium(TM) are trademarks of Cardium Therapeutics, Inc.

Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM), Excellagen(TM), Excellarate(TM), Osteorate(TM), Appexium(TM) and Linee(TM)are trademarks of Tissue Repair Company. (Other trademarks belong to their respective owners)

SOURCE Cardium Therapeutics

[Dicker69]

Antwort auf Beitrag Nr.: 40.126.111 von Ahorne am 09.09.10 15:31:29

Hi Ahorne,
Danke fürs reinstellenDie News war für den Kurs heute leider nicht hilfreicht!!

Gruss Dicker

[Dicker69]

Der Kurs soll noch nicht steigen! Seit Tagen wird der Kurs nach dem Anstieg mit einer Miniposi wieder zurück geholt!!!! Aber warum? Gruß Dicker

[Der.Eroberer]

Das ist der Nachteil eines 510(k)-Prozesses. Leider gibt es kein Enddatum an dem sich
der Kurs orientieren kann. Die Nachricht wird plötzlich und unerwartet kommen. Genau diese
Unsicherheit ist ein sehr guter Nährboden für einen großen Kursausschlag. Mit jedem Tag
rücken wir näher an den Zahltag.

[Ahorne]

Antwort auf Beitrag Nr.: 40.136.571 von Der.Eroberer am 11.09.10 14:41:06

so brauchen wir Geduld

Heute übrigens Konferenz:

Päsentation dazu: Cardium to Present at the Rodman & Renshaw 12th Annual Healthcare Investment Conference
http://media.corporate-ir.net/media_files/irol/77/77949/RODM…

Investment Highlights
© 2010 Cardium Therapeutics, Inc.

[Ahorne]

Antwort auf Beitrag Nr.: 40.145.100 von Ahorne am 14.09.10 08:31:40

wird die 200 SMA nachhaltig geknackt???

cu

http://www.barchart.com/chart.php?sym=CXM&style=technical&p=…

http://www.barchart.com/chart.php?sym=CXM&style=technical&p=…

[Der.Eroberer]

Schöner Aufschlag heute. So langsam beginnt es Spaß zu machen. Dabei ist der Zahltag noch
gar nicht gekommen. Vielleicht sind das schon die ersten Vorboten.

[Dicker69]

Antwort auf Beitrag Nr.: 40.164.341 von Der.Eroberer am 16.09.10 20:04:45

zwei fette Käufe, wissen Einige mehr als wir?

Gruss Dicker

[Dicker69]

Antwort auf Beitrag Nr.: 40.164.433 von Dicker69 am 16.09.10 20:21:46

sieht richtig Gut heute aus.........

[ericcartman]

Schöner Anstieg die letzten Tage. So langsam kommt das deutsche Lemmingverhalten in Gang.

[Der.Eroberer]

CXM ist ein Tier. Schon wieder über 7% im Plus. Ab 0,60 mache ich mir die ersten Gedanken über Teilverkäufe.

[Ahorne]

Antwort auf Beitrag Nr.: 40.169.756 von Der.Eroberer am 17.09.10 16:08:44

Cardium Therapeutics, Inc. (AMEX: $CXM) Big Reversal On This One Coming Up!? Watch This Video To Find Out!

http://stockpreacher.com/2010/09/14/cardium-therapeutics-inc…

[Ahorne]

Antwort auf Beitrag Nr.: 40.177.529 von Ahorne am 20.09.10 12:57:46

Cardium to Present at 10th Annual Biotech in Europe Investor Forum

the 10th Annual Biotech in Europe Investor Forum to be held September 29-30, 2010 at the Radisson Blu Hotel in Zurich. (no webcast)

http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-new…

[Der.Eroberer]

Schöner Anstieg! Habe die Hälfte meiner Anteile versilbert. Der Rest bleibt drin bis zum süßen Ende...

[Dicker69]

Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
9/29/2010 9:00 AM - PR Newswire

SAN DIEGO, Sept 29, 2010 /PRNewswire via COMTEX News Network/ --
Cardium Therapeutics (NYSE Amex: CXM) announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

Nitric oxide (NO) is a physiological mediator that has been shown to play an important role in enhancing wound healing. This new polymer-based technology represents a potentially novel and practical way to integrate the use of NO into a variety of wound healing products, which could include granulated and powder dressings, topical creams and gels, thin films and aqueous formulations, as well as electrospun fibers for dressings and bandages. Based on preliminary evaluations, these NO polymer complexes appear to be compatible with Cardium's Excellagen formulated collagen topical gel wound care dressing, which is currently the subject of a pending FDA 510(k) clearance application for marketing and sales in the United States. From a clinical development perspective, inhalable NO formulations have been approved for therapeutic use and the polymer components covered by this technology are currently used in FDA regulated medical products. Cardium believes that this versatile array of NO formulations offers the potential to commercially develop advanced wound dressings and therapeutics that could be applied to acute as well as chronic wound care settings.

"We are excited about the potential for the commercial development of this nitric oxide therapy initiative for wound healing and tissue regeneration. It opens the door for us to develop product extensions based on our formulated collagen product platform and to develop new products for other wound healing applications and in other medical settings that could include acute applications for military and emergency medical services. Previous efforts to use NO as a therapeutic agent have been limited by the short duration of its release and short half-life in the body, as well as by the intrinsic instability of traditional NO delivery agents. This novel and proprietary polymer-based technology allows for the localized delivery, activation and regulated release of NO over a period of time from one to several weeks, potentially enabling a new class of advanced wound therapeutics and dressings for both acute and chronic applications," stated Christopher J. Reinhard, Cardium's Chairman and Chief Executive Officer.

The technical advancements designed to provide regulatable and sustained release of NO were developed through research by Drs. Ping Lee and Yan Li at the University of Toronto and are currently covered by an exclusive option for wound care applications to Cardium. Dr. Lee is a professor and GlaxoSmithKline Chair at the Leslie Dan Faculty of Pharmacy at the University of Toronto. The business arrangements were coordinated and facilitated by MaRS Innovation, a commercialization agent that is supported by the Government of Canada that has partnered with 14 leading Toronto academic institutions to advance their discovery research toward commercialization.


Role of Nitric Oxide (NO) in Tissue Repair

Nitric oxide (NO) is recognized as a critical mediator of normal tissue repair. Working at the molecular, cellular and physiologic levels, essential wound repair processes such as granulation tissue formation, epidermal migration, collagen deposition and angiogenesis are all known to be regulated by NO bioactivity. Endogenously, NO is converted from arginine by three different nitric oxide synthases (NOS). It is known that inhibition of NO production impairs wound healing. The role of NO as a critical mediator is further supported by the fact that NO is involved in the up-regulation of the cytokine cascade, which serves as a key chemo-attractant for immune regulatory cells in the inflammatory phase of wound healing, as well as its transition into the proliferative phase for wound healing to progress to completion.

Nitric oxide has also been shown to enhance angiogenesis, endothelial cell migration, collagen synthesis, and wound closure, whereas NOS inhibition reduces or delays these processes. These cellular and physiological responses all suggest that NO plays a critical role in the overall wound healing process; and studies involving the application of NO further support its potential utility for wound healing and tissue repair and regeneration. For example, both topical application of NO gas or the administration NO donors appears to promote tissue repair and healing in animal models of diabetic wounds as well as in acute burn wound models. In addition, topical NO has also been shown to exhibit antimicrobial properties.

Based on these multiple beneficial activities, NO would appear to be an ideal therapeutic agent for various tissue injuries. Regulatable, localized and sustained delivery of NO would be particularly advantageous as NO would only be targeted to the specific site without eliciting systemic side effects. Despite these many advantages, the short duration of NO release and its short half-life in physiological fluids, as well as the intrinsic instability of available NO donors, has tended to prevent or limit the applicability of NO as a product opportunity for many wound care applications. Having regulatable and sustained release formulations offers the potential to overcome these technical limitations and enable the application of NO to a range of both acute and chronic wound healing applications.

About Excellagen

Excellagen is a highly-refined fibrillar bovine Type I collagen-based topical gel (2.6% collagen concentration) which has been evaluated in a controlled, double-blind randomized, multi-center Phase 2b clinical study at 23 U.S.-based medical centers for the treatment of chronic non-healing diabetic foot ulcers (the Matrix Study). Based on the pending 510(k) FDA submission, Excellagen would be indicated for the management of wounds, including partial and full thickness wounds, pressure ulcers, diabetic ulcers, chronic vascular ulcers and certain other wounds, such as surgical and trauma wounds.

Analysis of data from the Matrix Study indicates that the Excellagen product candidate appeared to be both safe and well tolerated, demonstrated improved wound area reductions and wound closure rates at 12 weeks following one or two treatments, and showed a statistically significant acceleration of wound healing during the first week following a one-time application compared to patients receiving standard of care therapy. In the first week following treatment, the radius of Excellagen-treated wounds decreased on average by 0.21 cm compared to 0.08 cm for standard of care-treated wounds (N=47, p = 0.018). The apparent treatment effect was particularly evident in patients with larger-sized wounds (>3.0 cm2). For example, at 12-weeks, 45% of all Excellagen-treated wounds achieved complete closure, compared to 31% in the standard of care group, representing a 45% overall improvement. For wounds >3 cm2 in area at screening, 33% of Excellagen-treated wounds achieved closure by 12 weeks compared to 0% for standard of care. In addition, 74% of all Excellagen-treated wounds achieved greater-than or equal to 90% wound area reduction at 12 weeks compared to 44% in the standard of care group, representing a 68% relative improvement.


About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium lifestyle medicinals brand platform. The Company's lead product candidates include: (1) Excellagen(TM) topical gel, for wound care management, which Cardium plans to market launch in the fourth quarter subject to pending FDA 510(k) clearance; and (2) Generx(R), a DNA-based angiogenic cardiovascular biologic for patients in international markets with coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that access to the commercial development rights to technology for novel and proprietary supramacromolecular polymer complexes to provide regulatable and localized topical delivery of nitric oxide (NO) for prolonged periods will be successful or will broaden and expand the Company's wound healing and tissue regeneration portfolio; that results or trends observed in vitro or in animal models will be reproduced or predictive of results in acute or chronic clinical settings; that NO will be sufficiently safe and effective in the promotion of wound healing and/or tissue regeneration; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that the U.S. Food and Drug Administration will grant marketing clearance of our product candidates or that we or a partner can successfully introduce our products into advanced wound care markets; that our product candidates will be perceived as being sufficiently safe and effective to lead to product advancement or partnering; that our product candidates offer the potential for simpler or more cost-effective treatments for physicians and patients than other products that currently are or will be on the market; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or its perceived value; that our products or product
candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; that discussions with potential strategic partners will be successful or that any partner will be able to efficiently and effectively commercialize our products in U.S. or international markets; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of biologics and other therapeutic products and devices, and in the conduct of human clinical trials and other product development efforts, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition and regulation, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2010 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics(TM) Generx(R) and MedPodium(TM) are trademarks of Cardium Therapeutics, Inc.

Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM), Excellagen(TM), Excellarate(TM), Osteorate(TM), Appexium(TM) and Linee(TM) are trademarks of Tissue Repair Company.

(Other trademarks belong to their respective owners)

SOURCE Cardium Therapeutics

Copyright (C) 2010 PR Newswire. All rights reserved

http://www.stockhouse.com/tools/?page=%2FFinancialTools%2Fsn…

[Ahorne]

Antwort auf Beitrag Nr.: 40.270.421 von Dicker69 am 05.10.10 22:53:42

Cardium Announces Market Launch of Linee - A Scientific Approach to Weight Management
http://finance.yahoo.com/news/Cardium-Announces-Market-prnew…

Press Release Source: Cardium Therapeutics; MedPodium On Monday November 29, 2010, 9:00 am EST

SAN DIEGO, Nov. 29, 2010 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced the addition of Linee™ to its MedPodium product line. Linee is a plant-derived non-prescription dietary supplement in the form of easy-to-use capsules designed to help promote healthy weight management. Cardium launched its MedPodium modern lifestyle brand in early November and the addition of Linee represents an important step toward broadening the line to include additional products designed to promote personal health and wellness.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

Linee is a nutritional supplement intended to be taken before meals to help manage appetite and control hunger as part of a comprehensive weight management program. The key ingredient of Linee is a potato-based protein extract (Appexium™ 150 mg) having Proteinase Inhibitor–II (PI-2) activity. Multiple scientific studies have shown that PI-2 can promote the release of a naturally-occurring peptide called cholecystokinin or CCK into the bloodstream. By increasing feelings of fullness or satiation, CCK can help to reduce the amount of daily food intake.* Linee's custom formulation contains a blend of Appexium PI-2, vitamin D3 and vitamin B12, which is filled into small, easy-to-swallow, pharmaceutical-quality capsules. As part of an overall weight management program, Linee may also be integrated into exercise, yoga and other fitness programs, or used in concert with popular weight-loss and dietary meal plan programs to enhance plan compliance and improve results.

"We are pleased to announce the addition of Linee to our MedPodium modern lifestyle brand initiative. We recently announced a co-development and strategic licensing agreement with BioZone Laboratories for the formulation, manufacture and licensing of a portfolio of up to 20 products to further broaden and expand our MedPodium brand initiative to encompass other healthy lifestyle formulations including novel metabolics, neurologics and aesthetics designed to address emerging health and well-being issues that are increasingly important in modern society. In addition to the MedPodium web boutique, we plan to market and sell certain products through various select distributors or retailers in the United States," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium.

About Linee

Linee™ is a dietary supplement based on the use of Proteinase Inhibitor-II (PI-2), a naturally-occurring protein derived from white potato that is a commonly consumed food and generally recognized as safe. While extracted and concentrated from white potato in the form of Appexium, the PI-2 protein is not altered chemically and it does not rely on absorbing fat or causing gastrointestinal (GI) tract fullness as in many other weight loss aids and dietary supplements that are sometimes not well tolerated due to discomfort, GI bloating and irregular bowel discharge. Based on multiple scientific studies, PI-2 appears to promote the release of a small peptide called cholecystokinin (CCK) that is naturally produced in the GI tract and can increase feelings of fullness and therefore help to reduce the amount of food eaten daily.*(1)(2) While exercise is important, years of research has suggested that the most effective means of ensuring weight loss in the average healthy person is by reducing total daily caloric intake. In a multi-site double-blind, placebo-controlled clinical study, patients receiving PI-2 twice daily before the two largest meals had statistically significant reductions in overall weight as well as in waist and hip measurements, as compared to placebo.*(3)

About MedPodium

MedPodium™ is a portfolio of premium, science-based, easy to use nutraceuticals, metabolics and aesthetics designed to promote health and well-being for today's active and professional lifestyles. MedPodium products are based on key ingredients that have been well characterized scientifically and shown to be capable of promoting healthy lifestyle interests such as enhancing energy, cognition, mood, sleep, weight management, fitness and aesthetics. The MedPodium brand also features improved product formulations including easy to use pills and capsules, novel, fast-acting oral drops and sprays, and innovative transdermal delivery systems. Additional information about MedPodium is located at www.medpodium.com

[ishav]

Ist jemand noch inevestiert? Die Zulassung lässt noch auf sich warten, obwohl schon über 13 Monate vergangen sind. Hat jemand Infos? Bei den Amis wird der Kurs seit Tagen unter 0,40 gehalten, Volumen ist auch nicht berauschend... Doch bei der guten Pipeline dürfte der Kurs bald durch die Decke gehen

[Ahorne]

Der Countdown läuft und läuft und läuft...

... warten auf die 510(k) Entscheidung für Excellagen (wound healing & repair)

bin auf Einstandkurs Niveau in letzten Jahr ausgestoppt worden... und diese Woche wieder rein 0.36 USD


http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-irh…

[Ahorne]

Antwort auf Beitrag Nr.: 41.265.983 von Ahorne am 25.03.11 12:22:56

mit Vorsicht zu geniessen:

http://investorshub.advfn.com/boards/board.aspx?board_id=160…

Current FDA plays!* updated 03/02/11

...

03/31 CXM 510k decision

...

[Ahorne]

Antwort auf Beitrag Nr.: 41.267.066 von Ahorne am 25.03.11 15:15:33

Top 10 Pharmaceutical Stocks with Highest Upside: MRNA, ALXA, CXM, DARA, CYCC, CYTR, PIP, AVNR, GNVC, CBP (Mar 28, 2011)


http://www.cnanalyst.com/2011/03/top-10-pharmaceutical-stock…

Below are the top 10 Pharmaceutical stocks with highest upside potential, UPDATED TODAY before 4:30 AM ET, based on the difference between current price and Wall Street analysts' average target price.

...
Cardium Therapeutics Inc. (AMEX:CXM) has the 3rd highest upside potential in this segment of the market. Its upside is 294.7%. Its consensus target price is $1.50 based on the average of all estimates.
...

[bluesrock]

Antwort auf Beitrag Nr.: 41.279.233 von Ahorne am 28.03.11 22:31:34

HI,
na dann, Daumen drücken. Bei entsprechenden Nachrichten bezüglich Zulassungen gehts wahrscheinlich einiges höher.

Grüße
Bluesrock

[Ahorne]

Antwort auf Beitrag Nr.: 41.279.382 von bluesrock am 28.03.11 23:25:04

Hallo Bluesrock

Ja, CXM wartet schon eine kleine Ewigkeit. War schon in 2010 dabei, gekauft... dann gings mal 15% raus und wieder runter... habe um den Einstandkurs verkauft... und seit kurzem wieder dabei...

Riskanter Wert, doch wie Du schon gesagt hast, sollte die 501k kommen, wirds abgehen.

Gruss

[Ahorne]

Antwort auf Beitrag Nr.: 41.279.382 von bluesrock am 28.03.11 23:25:04

in den Amis Foren wird der Tag der Entscheidung auf den 31.3 oder

The FDA has on their calender April 6/7 advisory committee meeting of the Biologics advisory committee is the most probable time that CXM will be discussed. If there is a PR that will come out the likely time would be Apr 8 or the week of Apr 11 - 15.

If CXM can just keep increasing by 1 - 2 cent per day it would be trading in the $.50+ range and a good POP could easily push this over $1.

GLTA

gelegt... doch das ist mit sehr viel Vorsicht zu geniessen.... die Pusher texten dieses bei jeder FDA Gelegenheit.

Fakt ist, FDA muss sich mal entscheiden... doch wann und wie, das ist 1 Million Dollar Frage...

[ishav]

Antwort auf Beitrag Nr.: 41.280.112 von Ahorne am 29.03.11 08:42:56

Das lange Warten auf die Zulassung nervt langsam. Aber in den nächten Tagen kommen die Geschäftszahlen und sicherlich auch eine Aussage zur FDA-Entscheidung. Der CEO hat ja schon einige Erfahrung mit der FDA und Zulassungen. Außerdem haben bietet Generx auch eine super Wachstumsstory. Mit Internetplattform MedPodium werden ja bereits Einnahmen generiert... Welche BioTech-Aktie kann das schon aufweisen. Zwei potenzielle Blockbuster und eine laufender Vertrieb und das bei einer Marktkapitalisierung von nur 24 Mio. Euro.

[Ahorne]

Antwort auf Beitrag Nr.: 41.283.860 von ishav am 29.03.11 17:03:28

Hallo ishav

bin ja mal gespannt, ob CXM mit der Internetplattform MedPodium Geld verdient.
Wir werden es bald wissen.

Gnerex traue ich viel zu.

Gruss

[asics01]

dass da eventuell die nächsten tage entscheidungen anstehen sollen,ist es aber verdammt ruhig in usa.
normal ist doch vor so einer entscheidung leben in der bude.

[Ahorne]

Zitat von asics01: dass da eventuell die nächsten tage entscheidungen anstehen sollen,ist es aber verdammt ruhig in usa.
normal ist doch vor so einer entscheidung leben in der bude.

ja, ruhig ist es... da hast Du recht, schon fast beängstigt...


31-Mar-11 Earnings announcement -> da sind wir mal gespannt
http://finance.yahoo.com/q/ce?s=CXM+Company+Events

& cooles Video:

Cardium Generx Cardio-Chant on YouTube
31-Mar-11 08:35 am New on YouTube;

http://www.youtube.com/watch?v=pjUndFhJkjM&feature=email

Generx® is a one-time, non-surgical angiogenic gene therapy being developed by Cardium Therapeutics (NYSE Amex: CXM). This new therapeutic approach employs human growth factor DNA to stimulate the heart's natural ability to grow additional blood vessels (angiogenesis) for patients with advanced coronary artery disease and chest pain (angina pectoris). The therapy is in clinical trials and is intended to offer an innovative non-surgical option for cardiac patients who currently undergo surgical procedures such as balloon angioplasty and stents, or "open heart" cardiac bypass graft surgery (CABG). Specific information about Generx and Cardium can be found on our website at: www.cardiumthx.com.

[asics01]

Antwort auf Beitrag Nr.: 41.298.457 von Ahorne am 31.03.11 17:58:46

im fall eines neins seitens der fda,wie weit wird es runter gehen ????

[Ahorne]

Zitat von asics01: im fall eines neins seitens der fda,wie weit wird es runter gehen ????

ja, dann wird übel... tiefer kurs... die company braucht irgendwann mal geld... verwässerung etc...

wie gesagt, das risiko ist nicht zu unterschätzen...

doch wie weit... keine Ahnung... vermutlich tief...

Hoffen wir einen positiven Entscheid!

[bluesrock]

no risk- no fun
Im Pharma und Biotechbereich sind Chancen und Risiken immer gleichgewichtig und zudem braucht man immer geduld. Das sollte man wissen bevor man investiert. Generx und Excellagen sind zwei Top-Produkte, die bei Marktzulassung weltweit gesucht werden. 2011 wird für Cardium Therapeutics entscheidend ob Top oder Flop oder anders gesagt fette, fette Gewinne oder Totalverlust.
Gestern gabs auf jedenfall schon mal gute Umsätze in USA und der Youtube Beitrag macht Laune auf mehr.

Grüße
Bluesrock

[Ahorne]

Antwort auf Beitrag Nr.: 41.300.645 von bluesrock am 01.04.11 00:40:40

ich bin auch guten Mutes

hier noch die Zahlen:

Cardium Presents Fourth Quarter and Year-End 2010 Financial Results and Recent Developments
http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-new…

Gruss

[Ahorne]

Antwort auf Beitrag Nr.: 41.300.967 von Ahorne am 01.04.11 07:56:25

hier noch eine Zusammenfassung:

Cardium Therapeutics Q4 Profit Plunges - Quick Facts

(RTTNews) - Cardium Therapeutics (CXM: News ) posted fourth-quarter net income of $443 thousand or $0.01 per share, compared with $9.3 million or $0.17 per share in the comparable quarter last year.

The decrease in net income during this period was due to a favorable change in fair value of derivative liabilities of $1.5 million recorded in the fourth quarter of 2010 compared to $11.4 million recorded in the fourth quarter of 2009.

Non-GAAP net loss widened to $1.41 million from $1.30 million in the same quarter last year. The company reported loss per share of $0.02, same as last year.

Revenues for the fourth quarter rose to $244 thousand from $183 thousand in the prior year quarter.

Click here to receive FREE breaking news email alerts for Cardium Therapeutics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact [e-mail]

[bluesrock]

Antwort auf Beitrag Nr.: 41.301.314 von Ahorne am 01.04.11 09:01:22

Ich liebe diese Ruhe vor dem Sturm

[asics01]

Antwort auf Beitrag Nr.: 41.331.199 von bluesrock am 07.04.11 00:24:02

ist wohl nur ein laues lüftchen

[bluesrock]

Antwort auf Beitrag Nr.: 41.336.298 von asics01 am 07.04.11 19:33:23

und wenn?
ein laues Lüftchen an heißen Tagen finde ich ganz sympatisch. Hast du etwa heute deswegen verkauft?

[asics01]

Antwort auf Beitrag Nr.: 41.336.940 von bluesrock am 07.04.11 21:37:15

und wenn?
ein laues Lüftchen an heißen Tagen finde ich ganz sympatisch. Hast du etwa heute deswegen verkauft?

nicht das ich wüsste,ich habe meine in usa geordert und werde sie auch behalten. der fda termin zieht sich wie gummi,ob da wohl alles in ordnung ist??????

[asics01]

wer glaubt denn noch an diese story 1 1/2jahre nach einreichung der daten,ohne einen kommentar seitens der fda?????

[asics01]

Cardium Therapeutics, Lannett: Dealing With Debilitating Biotech Situations 4 comments | by: Spencer Knight April 11, 2011 | about: CXM, LCI Font Size: PrintEmail Recommend 1 Share this page
Share0 In a previous article, How to Maneuver the Biotech Sector, I mentioned how FDA approvals can lead to a very wealthy short term portfolio. I also discussed how biotech stocks with a strong pipeline can lead to long term growth that beats the S&P.

However, I will now follow up on those ideas with a warning to investors: Even if the FDA does not act upon an NDA in a timely manner, a company can be stuck with a financial struggle. Which leads to a company being in the dark as to what to do. For instance, companies plan on marketing a product promptly after submitting a New Drug Application, NDA, or an FDA 510(k), which is for products that already exist in the market, or are being reintroduced. Now is a good time to apply this to Cardium Therapeutics (CXM) and Lannett (LCI), since both are currently facing this problem.

Cardium Therapeutics is a small biotech company with a share price that is steady in the mid $0.30 region. According to Cardium, the company is "focused on the acquisition and strategic development of new and innovative bio medical opportunities that have the potential to address unmet medical needs." Currently Excellagen is Cardium's closest drug to being cleared by the FDA. Unfortunately for Cardium, the FDA has not acted upon the company's 510(k), filed in December 2009. A deion of Excellagen from Cardium can be read below:

Excellagen™ is a highly-refined fibrillar bovine Type I collagen-based topical gel (2.6% collagen concentration) which has been evaluated in a controlled, double-blind randomized, multi-center Phase 2b clinical study at 23 U.S.-based medical centers for the treatment of chronic non-healing diabetic foot ulcers (the Matrix Study). Based on the Company's pending 510(k) FDA submission, Excellagen would be indicated for the management of wounds, including partial and full thickness wounds, pressure ulcers, diabetic ulcers, chronic vascular ulcers and certain other wounds, such as surgical and trauma wounds. The Excellagen product platform provides the opportunity to develop and introduce additional new product opportunities by incorporating other agents into the Excellagen formulation, including antimicrobials, DNA and/or other biologics, which will be designed to address particular wound healing and other tissue repair applications.

Excellagen is used for patients with foot ulcers from prolonged diabetes. Foot ulcers from diabetes can lead to amputation, paralysis in the feet and legs, and even death in severe cases. The results of Excellagen are very positive and show closure of the wounds which can save people from facing amputations. Despite the positive results, the FDA has yet to clear Excellagen. If Excellagen were to be approved, the market for the product will grow exponentially since diabetes is an epidemic that is estimated to double in 25 years.

Because the FDA has delayed the approval process for so long, Cardium has been forced to take actions it may never have planned. The most significant effect that the delay of Excellagen has had on Cardium is constant problems with the New York Stock Exchange (NYSE) listing requirements. Since Cardium has not been able to maintain the required stockholder equity, the company has been warned several times that it will be delisted from the NYSE.

The first time Cardium was warned was December 23, 2008. In order to make enough money to stay publicly listed, Cardium had to sell InnerCool Therapies for $11.25 million to make up the deficit. Even though this kept Cardium from being moved to the OTC Bulletin Board, it did cause Cardium to lose part of its business which had a bright future. Less than a year later, on November 9, 2009, Cardium received another notice that the company was noncompliant with the NYSE standards. Cardium was able to reach compliance after the company raised $11.3 million dollars through a direct equity offering. In both instances, Cardium was able to raise enough money for one year to stay publicly traded. This allowed the company extra time for the FDA to clear Excellagen. Not surprisingly, on September 30, 2010 Cardium received another notification stating that it must fulfill the requirements of the NYSE to stay listed. Currently Cardium has submitted a plan to the NYSE, but the company has yet to describe that plan.

The main point to take away from this is that Cardium is in quite a bind with the long delay by the FDA. Also, it must be noted that the 510(k) is not like a standard NDA because the FDA does not have to give an exact action date like it does for typical NDAs. This is a problem for drug companies, such as Cardium, that do not have major products available for consumers. It may come to a point where Cardium will have to decide to either sell MedPodium, or be taken off the major public offering block until Excellagen is cleared. If you do decide to invest in Cardium, or another company waiting for a 510(k), then you must be willing to deal with what could be a long waiting period. In the case of Cardium, there is very little volatility since most investors are waiting on the 510(k) to be cleared or rejected, and this pattern is seen in other companies facing the same situation.

On the other hand, Lannett has been in quite a precarious situation since it filed a standard NDA for Morphine Sulfate Oral Solution in February 2010. It has not yet heard back from the FDA and no action date is set. Lannett's Morphine Sulfate was on the market until July 24, 2010 when the FDA started a crackdown on non-FDA approved Generally Recognized as Safe and Effective (GRASE) products. The main problem that the FDA has with GRASE products is that the manufacturing facilities may not be up to par. Therefore, the FDA inspected Lannett and Cody Laboratories (a fully owned subsidiary of Lannett) for any problems. It is simple for Lannett: Once the factories are deemed safe, Morphine Sulfate will be approved. However, as of now, either Lannett has not yet corrected the problems with its factories or the FDA is still reviewing the observations. I contacted Keith Ruck, VP of Finance and CFO for Lannett, on March 30, 2011 and he stated that my guess is as good as his as to when the FDA will report the inspection results, and that the same applies as to when Lannett will hear additional news from the FDA.

Cardium is a great example for Lannett because we could see continued inspections of the Lannett properties, which would lead to longer delays. It is not uncommon for the FDA to inspect biotech properties, but due to the minor observations that have been found it will be difficult for Morphine Sulfate to get approved as soon as investors would like. Of course, due to the uncertainty of this situation, the FDA could make a ruling within the next week. That being said, I see the FDA inspecting Lannett until everything is corrected to make sure that the facilities will produce safe drugs.

The biggest note to take home is that some biotech companies can wait for long periods of time before getting a safe drug approved to be marketed. This usually leads to a price drop in the stock since short investors will eventually get frustrated and move their money elsewhere.

[Ahorne]

war mal kurzfristig Investiert und mit 10% Verlust verkauft
Immer noch eine Hängepartie, aber wenn die Genehmigung der FDA kommen sollte... sehen wir hier andere Kursen.

Watch List! (again )

Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
SAN DIEGO, Aug. 15, 2011 /PRNewswire via COMTEX/ --

http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-new…

[Ahorne]

Antwort auf Beitrag Nr.: 41.960.333 von Ahorne am 16.08.11 19:40:24

Cardium Announces Receipt of $1.1 Million in Funds from Philips' Acquisition of Innercool Therapies
http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-new…

SAN DIEGO, Aug. 18, 2011 /PRNewswire via COMTEX/ --

Cardium Therapeutics (NYSE Amex: CXM) today reported that it had received funds corresponding to the final $1.1 million payment from Royal Philips Electronics in connection with Philips' acquisition of Innercool Therapies from Cardium. The release of funds from restricted cash represents the receipt of all amounts escrowed in connection with the Innercool acquisition by Philips, less an adjustment of approximately $50,000 to correct for working capital revisions and costs in connection with the closing of the $11.25 million transaction.

"Cardium's strategic repositioning and sale of Innercool Therapies to one of the world's leading companies providing healthcare and other products, represents the first monetization from the Company's biomedical investment portfolio, and we are now focused on other opportunities with the potential for future partnering," noted Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium.

[ericcartman]

Zulassung, Yes endlich

[asics01]

Antwort auf Beitrag Nr.: 42.192.554 von ericcartman am 10.10.11 16:02:31

von was war hier die rede bei zulassung??? 1-2$ da sind wir aber noch weit weg.egal besser als nichts
aktuel 0,34$.

asics

[asics01]

Cardium Announces FDA 510(k) Clearance for U.S. Marketing and Sale of Excellagen Formulated Collagen Topical Gel for Diabetic Foot Ulcers, Pressure Ulcers and Other Dermal Wounds


Professional-Use, Sterile, Syringe-Based Topical Gel: Outcomes-Focused Wound Care Management


SAN DIEGO, Oct. 10, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen™ professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds. Directions for use indicate the application of Excellagen immediately following surgical debridement, which is routinely practiced in the treatment of diabetic foot ulcers and other dermal wounds.

(Photo: http://photos.prnewswire.com/prnh/20111010/LA83118)

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

Excellagen is a highly-refined fibrillar flowable bovine collagen topical gel (2.6%) that will initially be marketed as a sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers following surgical debridement procedures. In addition to diabetic foot ulcers, Excellagen is also cleared for use in the management of other dermal wounds including partial and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds.

The Company believes that Excellagen provides a new sterile, syringe-based advanced wound care option as there are no other collagen-based wound management products available for professional use in the United States that are considered comparable to Excellagen in terms of its overall formulation, fibrillar nature and product format. Other professional use collagen-based products include granulated collagens that require mixing prior to use, as well as a variety of sheet-based products.

Cardium's Excellagen fibrillar collagen topical gel also represents a new technology and product platform that allows for the potential development of a portfolio of other advanced wound care and therapeutic products. Cardium's Gene Activated Matrix (GAM) technology represents one extension of Cardium's newly FDA-cleared flowable, fibrillar collagen-based matrix for the localized topical delivery of agents that could include anti-infectives, antibiotics, peptides, proteins, small molecules, DNA, stem cells, differentiated cells and conditioned cell media. The Excellagen product is based on Cardium's newly-established manufacturing process, which allows for sterile fill of ready-to-use, single-use syringes for topical application. In addition, the advancement of Excellagen provides the opportunity to perform post-clearance studies to pursue therapeutic claims for the treatment of non-healing diabetic foot and pressure ulcers, as well as other wounds, following findings from Cardium's Matrix clinical study which showed that formulated collagen can significantly accelerate reductions in wound radius immediately following application compared to standard of care therapy in diabetic foot ulcers, and can support platelet activation and release of the wound healing protein, Platelet-Derived Growth Factor (PDGF). These findings were published in the peer-reviewed journal official journal of the Wound Healing Society, Wound Repair and Regeneration, (2011) 19: 302-308, available at www.cardiumthx.com/pdf/ExcellagenPaper_WoundRepair.pdf.

"This FDA regulatory clearance is a significant milestone for Cardium and represents an important step forward in the advancement of our Excellagen technology platform, which we developed and commercially advanced following Cardium's acquisition of the Tissue Repair Company. We look forward to the launch of Excellagen and to helping address the large and rapidly-growing advanced wound care market. We are continuing to work with potential new collaborative partners and exploring additional product opportunities for our Excellagen formulation and additional advanced wound care products that could be based on the Excellagen technology platform. We recently posted an investor presentation on Excellagen to our website that can be accessed at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-pre… The business focus of our portfolio is centered on health sciences and regenerative medicine and we look forward to initiating the late-stage/registration Aspire clinical study for our Generx® angiogenic therapy as a potential new treatment option for patients with myocardial ischemia due to advanced coronary disease," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium.

About Excellagen

Excellagen is a new FDA-cleared professional-use, sterile, syringe-based advanced wound care product designed to support the management of chronic diabetic foot ulcers and other dermal wounds following surgical debridement procedures. It is a highly-refined fibrillar flowable bovine collagen topical gel (2.6%) intended to support a favorable wound healing environment. Excellagen is intended for use at one- to two-week intervals following surgical debridement (with weekly outer dressing changes) and will initially be supplied in the form of a kit consisting of four sterile, pre-filled, ready to use single-use syringes, each containing 0.5 cc of Excellagen formulated collagen topical gel (2.6%), and four sterile flexible applicators to facilitate topical administration to the wound site over a course of up to four treatments. One Excellagen 0.5 cc syringe is intended to treat wounds up to 5.0 cm2 in size. Based on the properties of Excellagen's highly purified, fibrillar collagen, it requires storage at standard refrigeration temperatures (2 - 8 degrees C). Detailed information about Excellagen, including the product's directions for use, is available at www.excellagen.com. To view the new informational video, Excellagen: A New Wound Care Pathway, please visit http://www.youtube.com/watch?v=D2GYCYc_8JE.

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform. The Company's lead commercial product Excellagen™ topical gel for advanced wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that we can successfully introduce Excellagen into wound care markets for the treatment of diabetic foot ulcers or other dermal wounds; that we can have Excellagen or our other products manufactured in a successful and cost-effective manner; that we can attract suitable commercialization partners for our products or that such partners will successfully commercialize our products; that our product or product candidates will not be unfavorably compared to other competitive products that may be regarded as safer, more effective, easier to use or less expensive; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures or in actual use; that clinical studies and regulatory clearances even if successful will lead to product advancement or partnering; that that FDA or other regulatory clearances or other certifications, or other commercialization efforts will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; that new collaborative partners will be found; that additional product opportunities will be established; or that that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2011 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™, and Nutra-Apps™ are trademarks of Cardium Therapeu
•























Sitemap|
Company List|
Help/FAQ|
Advertise With Us|
Link to Us|
Contact Us
About NASDAQ OMX|
Listing Center|
Copyright|
Disclaimer|
Trademarks|
Privacy Statements|
Annual Reports
Careers|
Custom Logo Ticker|
NASDAQ Toolbar|
Newsletter Signup|
Feedback






Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

[franzisca]

was ist jetzt los?....Shorter?

[Ahorne]

Antwort auf Beitrag Nr.: 42.208.822 von franzisca am 13.10.11 16:34:47

bin wieder drin

[franzisca]

Antwort auf Beitrag Nr.: 42.221.405 von Ahorne am 17.10.11 16:00:48

Ich auch!

[Ahorne]

Antwort auf Beitrag Nr.: 42.223.087 von franzisca am 17.10.11 21:32:52

welcome on board

Im YahooForum ist ein wenig mehr los:
http://messages.finance.yahoo.com/mb/CXM

[Biohero]

Seid vorsichtig CXM geht das geld aus es reicht nur noch für ca 3 monate . Da CXM das produkt selbst vermarkten will rechne ich mit einer saftigen Kapitalerhöhung .


Although we believe that we have sufficient capital to support our operations through January 1, 2012, we are still a development stage company subject to all the risks and uncertainties that are typical in the lifecycle stage of our business.

We intend to secure additional working capital through sales of additional debt or equity securities. We do not have any arrangement for financing in place at this time, nor can we provide any assurance about the availability or terms of any future financing.

[ishav]

Jetzt geht das hier auch noch los. Wieder so ein Basher, der in die Glaskugel schaut und Dilution sieht Eine Kapitalerhöhung wird irgendwann kommen, aber sicherlich nicht zu diesen niedrigen Kursen. Vorher werden erstmal ein paar Aktien verkauft, um Geld in die Kasse zu spülen. Sicherlich steht die Firma auch schon in Verhandlungen mit möglichen Vertriebspartnern für Excellagen. Schließlich hatten die fast zwei Jahre Zeit, um sich auf dem Markt umzuschauen. Sollte ein kompetenter Partner gefunden werden, dann dürften die Lizenzeinnahmen ausreichen, um den Blockbuster "Generx" weiterzuentwickeln. Dieses Herzmittel ist dann der richtige Gewinnturbo. Man sollte nicht vergessen, wer dieses Medikament mitentwickelt hat. Schering hat sicherlich gute Vorarbeit geliefert...also Gewinne erstmal laufen lassen. Der richtige Anstieg kommt erst noch.

Biohero, noch viel Glück beim Bashen...willst natürlich billig rein kann ich verstehen.

[Ahorne]

Antwort auf Beitrag Nr.: 42.224.802 von ishav am 18.10.11 11:06:44

so sehe ich das auch.
CMX ist attraktiv bewertet; besonders von "Generx" halte für sehr viel ... und das die Company bald Geld braucht ist den meisten klar... Kapitalaufnahme ist per se nichts schlechtes...


hier noch eine Meinung von WOOW Trading:

Home > $CXM a Bullish Bet:
http://woowtrading.com/2011/10/18/cxm-a-bullish-bet-next-goo…

[Ahorne]

neue Präsentation Cardium Therapeutics, Inc. (CXM) -> Generx®:

http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9N…

Generx® Highlights

 Generx [Ad5FGF-4] represents a new therapeutic class of regenerative
medicine DNA-based biologics for interventional cardiology that is designed
to stimulate the natural growth of microvascular circulation for the treatment
of patients with myocardial ischemia due to advanced coronary disease.
Generx is administered one-time, using a cardiac catheter.

 Generx is being currently developed, in markets outside the U.S., as
treatment alternative for patients who may not have access to costly and
invasive advanced mechanical revascularization procedures, including
coronary artery bypass surgery and angioplasty/stents, or may no longer be
optimal candidates for these procedures.

 Ad5FGF-4 has been evaluated in four clinical studies in North America and
Western Europe at over 100 medical centers with over 650 patients
participating in these studies. Data from the clinical studies have been
published in leading peer reviewed medical journals.

- The product appears safe and capable of improving microvascular circulation in
certain patients, as measured by SPECT imaging, and improvements using
standard ETT assessments.

[ishav]

Die neue Gernerx-Präsentation sieht gut aus. Besonders der Punkt gefällt mir sehr gut:

First DNA-based biologic
to advance to U.S. FDA
Phase 3 (with fast track
status) and Registration /
Phase 3 Study in Russia

Fast track status ist hier sehr positiv zu werten, da das Produkt als wichtiges Medikament eingestuft wurde. Nicht ohne Grund hat cxm im zurückliegenden Jahr ein cash grant of approximately $245,000 bekommen.Mit der Pipieline rückt cxm als potentieller Kaufkandidat in den Fokus der großen Pharmaunternehmen. The sky is the limit...

[Biohero]

Antwort auf Beitrag Nr.: 42.224.802 von ishav am 18.10.11 11:06:44

Although we believe that we have sufficient capital to support our operations through January 1, 2012, we are still a development stage company subject to all the risks and uncertainties that are typical in the lifecycle stage of our business.

Oha ich bin ein basher weil ich das wiedergebe was die Firma selber sagt OKAY . Schauen wir mal auf den kurs ups die Aktie hat ja fast 10 cents verloren .

Egal manchmal ist es besser aus eignen fehler zu lernen gell

http://de.advfn.com/p.php?pid=staticchart&s=AMEX%3ACXM&p=0&t…

[asics01]

cxm ist ganz klar ein übernahme kandidat, ich sehe in excellagen und generex 2 blochbuster und das bei einer mk von 44 mio $.kann doch eigentlich nur steigen, oder ?????
bin im schnitt seit 0.17$ und gebe unter 1$ nichts ab

asics

[ishav]

Nach so einen rasanten Anstieg sind Gewinnmitnahmen verständlich und auch ganz gesund. Die typischen Trader denken halt nur in Tagen und sehen die ganze Story nicht. Soll mir auch recht sein, dann kann ich weiter aufstocken...

Man lernt ja aus eigenen Fehlern, gell

[Ahorne]

schöne Homepage:

http://www.excellagen.com/index.html

[asics01]

das ist der hammer wie cxm immer runtergeprügelt wird,vor der zulassung auf 0,13$,und jetzt wieder auf 0,42$.
jede andere aktie wäre nach solchen news,und aussichten durch die decke.bin mal gespannt wann wir wieder die 0,30$ sehen????
liegt wohl auch am momentanem umfeld,trotzdem alles nicht ganz nachvollziehbar.

asics

[ishav]

Die Börse ist halt ein Spielcasino. Da werden die Kurse in die gewünschte Richtung bewegt, um das große Geld zu verdienen. Ist mir schon bei einigen Bio-Techs aufgefallen, dass die Kurse vor positiven News massiv gedrückt werden, um billig einsteigen zu können. Bei cxm war es ja genauso...kurz vor der Zulassung auf 0,13 $ gedrückt. Nun ein ähnliches Spiel, um nochmals billig einzusteigen. Also, einfach ruhig bleiben , die 1,50 $ sehen wir noch bis Jahresende.

[asics01]

über cxm mache ich mir auch keine sorgen,trotzdem nervig das ganze.
sag mal weisst du wie es mit excellagen weiter geht auserhalb der usa???
danke

asics

[Ahorne]

Cardium Therapeutics and Oncothyreon Poised for Growth
The Paragon Report Provides Equity Research on Cardium Therapeutics & Oncothyreon

http://finance.yahoo.com/news/Cardium-Therapeutics-iw-115340…

http://www.paragonreport.com/CXM

[Ahorne]

Zitat von Ahorne: Cardium Therapeutics and Oncothyreon Poised for Growth
The Paragon Report Provides Equity Research on Cardium Therapeutics & Oncothyreon

http://finance.yahoo.com/news/Cardium-Therapeutics-iw-115340…

http://www.paragonreport.com/CXM

Ich habe mir den Report herunter geladen... Useless. Schade.

[asics01]

Antwort auf Beitrag Nr.: 42.242.384 von Ahorne am 21.10.11 14:45:00

wenn das noch so ein paar tage weitergeht sind wir wieder bei 0,13$

[asics01]

holen die sich einen partner ins boot,oder ziehen die das alleine durch?????

[ishav]

Die werden sich einen Partner ins Boot holen, um Excellagen zu vermarkten. Da cxm auch in Europa und Asien aktiv ist, wird es sicherlich ein großeres Pharmaunternehmen sein. Schaut Euch einfach mal die Verbindungen aus der Vergangenheit an...Collateral Therapeutics (CEO Reinhard war Mitgründer) wurde von Schering gekauft, die dann von Bayer geschluckt worden. Der CEO dürfte sich also gut mit europäischen Unternehmen auskennen.

Der Schachzug Generx in Russland zu platzieren ist auch ganz clever und das neue Update über den indischen Markt schaut interessant aus. Neue Märkte sind für Medikamente sinnvoll, da das amerikanische Gesundheits- und Gesamtsystem in Zukunft harte Einsparungen durchführen muss. Viel Geld für gute Medikamente wird da nicht zur Verfügung stehen.

[Ahorne]

Antwort auf Beitrag Nr.: 42.245.453 von ishav am 22.10.11 11:31:43

Danke für Deine Einschätzung:

Hier noch was:

What a Fragmented Diabetic Foot Ulcer Treatment Market Really Means: SNWV, CAPS, BIEL, CXM

By Matthew Briar
Published: October 21, 2011
http://www.smallcapnetwork.com/What-a-Fragmented-Diabetic-Fo…

[Ahorne]

Zitat von Ahorne: Danke für Deine Einschätzung:

Hier noch was:

What a Fragmented Diabetic Foot Ulcer Treatment Market Really Means: SNWV, CAPS, BIEL, CXM

By Matthew Briar
Published: October 21, 2011
http://www.smallcapnetwork.com/What-a-Fragmented-Diabetic-Fo…

Wie sieht Ihr die Konkurrenz Situation für Excellagen?

thx & gruss

[asics01]

dann könnte ja alles bevor es richtig mit excellagen losging,wieder vorbei sein....
und generex braucht noch ein paar jahre
ich werde auf jedenfall den nächsten anstieg(sofern er kommt)nutzen und meine teile raushauen.
die haben es wohl selber verbockt,ich weiss nicht wo das problem lag um 2 jahre auf die zulassung zu warten.überlege mal das wäre ein jahr früher passiert,wo auch das umfeld ruhiger war da hätten die bis heute ihre kohle verdient.aber hätte der hund nicht.....

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.245.833 von Ahorne am 22.10.11 15:16:56

hier einige Meinung zu diesem Thema aus dem Yahoo Forum:

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

[asics01]

bleibt jetzt nur zu hoffen,dass schnell ein partner präsentiert wird um excellagen optimal zu vermarkten.
vielleicht ist excellagen auch besser wie die momentanan präparate die am markt sind, und die folgen werden.

[asics01]

Nachrichten zum Transdel-Verfahren sollten auch die nächsten Tage kommen. Wenn Cardium hier noch zum Zuge kommt, dann gibt es noch einen weiteren schub

[Ahorne]

Neue Präsentation -> 25.10.2011

http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-pre…

[Biohero]

@asics

Transdel ist der reinste Schrotthaufen ihr einziges produkt ketotransdel ist hoffnungslos in P3 gescheitert ,du solltest lieber hoffen das CXM nicht zum zuge kommt .

Fassen wir mal zusammen :

CXM is kurz davor sein Amex listing zu verlieren
Cash reicht nur noch bis anfang Jan 2012
Excellagen hat etliche konkurrenten mit teilweise bessere wirkungen

Lasst euch nicht blenden von irgendwelchen seeking alpha artikeln die sind meistens von den yahoo pumper geschrieben .

[ishav]

So wie ich das sehe, gibt es z.Zt. nur ein Konkurrenzprodukt "Regranex". Soll aber mit Krebsrisiken behaftet sein. Somit ist Excellagen das einzig zugelassene Wundheilgel-Produkt in den USA ohne böse Nebenwirkungen. Es gibt zwar noch eine Reihe von anderen Produkten, die aber wesentlich schwieriger anzuwenden sind (Mischprodukte). Die Frage ist nur, ob es nicht schon andere Therapien für die Wundheilung gibt (Laser usw.).

Das der Kurs so runter geht, liegt sicherlich auch an der "schlechten" PR von Cardium. Hier sind halt Mediziner am Werk, die keine Lust auf Aktionäerspflege legen. Bis zum Q3 Report im November wird bestimmt nicht viel Wind gemacht. Einfach abwarten und Stücke einsammeln. Denn die Fakten stimmen bisher, im Gegensatz zu vielen anderen Biotechs.

[asics01]

So wie ich das sehe, gibt es z.Zt. nur ein Konkurrenzprodukt "Regranex". Soll aber mit Krebsrisiken behaftet sein. Somit ist Excellagen das einzig zugelassene Wundheilgel-Produkt in den USA ohne böse Nebenwirkungen. Es gibt zwar noch eine Reihe von anderen Produkten, die aber wesentlich schwieriger anzuwenden sind (Mischprodukte

wenn dem so wäre ,dann würde der kurs wohl in anderen regionen stehen.
egal ich habe gestern kurzentschlossen meine teile mit fast 100% rausgehauen,vielleicht zocke ich bei 0,30$ wieder mit.

[Ahorne]

Atherosclerosis or Coronary Artery Disease Therapeutics (CAD) - Pipeline Assessment and Market Forecasts to 2018

NEW YORK, Oct. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.prnewswire.com/news-releases/atherosclerosis-or-coronary-artery-disease-therapeutics-cad---pipeline-assessment-and-market-forecasts-to-2018-132680888.html

Textauszug:

Analysis of the current and future competition in the seven key countries' Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market. The key market players for Atherosclerosis or Coronary Artery Disease (CAD) in future will be GlaxoSmithKline plc, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Isis Pharmaceuticals, Inc, Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company and Cardium Therapeutics

[Ahorne]

Zitat von Ahorne: Atherosclerosis or Coronary Artery Disease Therapeutics (CAD) - Pipeline Assessment and Market Forecasts to 2018

NEW YORK, Oct. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.prnewswire.com/news-releases/atherosclerosis-or-c…

Textauszug:

Analysis of the current and future competition in the seven key countries' Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market. The key market players for Atherosclerosis or Coronary Artery Disease (CAD) in future will be GlaxoSmithKline plc, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Isis Pharmaceuticals, Inc, Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company and Cardium Therapeutics

schaut Euch mal die Namen an:

- Analysis of the current and future competition in the seven key countries' Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market. The key market players for Atherosclerosis or Coronary Artery Disease (CAD) in future will be GlaxoSmithKline plc, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Isis Pharmaceuticals, Inc, Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company and Cardium Therapeutics

[asics01]

willst du damit sagen,dass einer von denen sich cardium einverleiben will???
aus dieser aktie werde ich nicht schlau,obwohl ich mir schon wieder überlege reinzugehen, aber erst bei 0,35$.

[Ahorne]

Antwort auf Beitrag Nr.: 42.275.823 von asics01 am 29.10.11 16:42:50

Es wäre intressant zu wissen was genau im Bericht steht.
Aber das Cardium neben all diesen Bigs erwähnt wird; ist ein Zeichen das sie zu den "key market player -> Atherosclerosis or Coronary Artery Disease (CAD) gehören.

Das könnte durch aus Begehrlichkeiten wecken.

Ja, der Kursverlauf für mich auch nicht Nachvollziehbar... doch vieles ist halt offen... Vorallem die Finazierung für 2012... Ich hoffe sie werden das intelligent lösen

[asics01]

ist nun excellagen das beste momantan am markt???
wieviel wird momentan verkauft,und zu welchem preis???
vertreiben sie es alleine, oder wird demnächst der weisse ritter präsentiert????
wenn die überleben wollen müssen die in die gänge kommen,denn die konkurenz schläft nicht.
die hatten doch 2 jahre zeit im vorfeld die weichen zu stellen

[Ahorne]

Eine Randnotiz:

Medifast Inc. Third Quarter Earnings Sneak Peek
http://finance.yahoo.com/news/Medifast-Inc-Third-Quarter-wsc…

Competitors to Watch: eDiets.com Inc. , Weight Watchers Intl., Inc. , NutriSystem Inc. , Herbalife Ltd. , Schiff Nutrition Intl. Inc. , Reliv International, Inc , Hi-Tech Pharmacal Co. , Cardium Therapeutics Inc. , Nutraceutical Int’l Corp. , and Hospira, Inc. .

[Ahorne]

Eine Randnotiz:

Medifast Inc. Third Quarter Earnings Sneak Peek
http://finance.yahoo.com/news/Medifast-Inc-Third-Quarter-wsc…

Competitors to Watch: eDiets.com Inc. , Weight Watchers Intl., Inc. , NutriSystem Inc. , Herbalife Ltd. , Schiff Nutrition Intl. Inc. , Reliv International, Inc , Hi-Tech Pharmacal Co. , Cardium Therapeutics Inc. , Nutraceutical Int’l Corp. , and Hospira, Inc. .

[Ahorne]

heute News?

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

--> Searched Cardiumthx on twitter and found an interesting link from PR Wire's twitter acct...see link..

http://photos.prnewswire.com/medias/switch.do?prefix=/appnb&…

[ishav]

Denke nächste Woche kommen endlich mal News. Mein Tipp ist Novartis als Partner...

[Ahorne]

Antwort auf Beitrag Nr.: 42.337.620 von ishav am 11.11.11 15:11:48

Grüezi

Das wäre doch eine Adresse

[Ahorne]

ps:

50 Most Searched Stocks
http://www.thelion.com/bin/forum.cgi?cmd=most_searched


Symbol Name
CXM Cardium Therapeutics
PRMW Primo Water Corporation
PEIX Pacific Ethanol
ARWR Arrowhead Research Corporation
CYTR CytRx Corporation
ZGNX Zogenix, Inc.
TAT TransAtlantic Petroleum Ltd.
OXGN OXiGENE
RENN RENREN INC.
RDN Radian Group
...

[Ahorne]

Cardium Presents Third Quarter 2011 Financial Results and Reports on Near-Term Milestones

http://finance.yahoo.com/news/Cardium-Presents-Third-prnews-…

[Ahorne]

Form 8-K for CARDIUM THERAPEUTICS, INC.
16-Nov-2011
http://biz.yahoo.com/e/111116/cxm8-k.html

K-8 kann vieles Bedeuten: http://en.wikipedia.org/wiki/Form_8-K

Schaun wir mal...

[asics01]

hallo ahorne

wie schätzt du persönlich cardium und besonders excellagen ein???
ich glaube man weiss erst nach einem vielleicht deal, was cardium bzw excellagen wert ist.sie sind ja gerade in verhandlungen mit möglichen partnern
dem kursverlauf nach wird nicht viel von excellagen gehalten

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.367.227 von asics01 am 18.11.11 06:22:40

hallo asics

die erste euphorie über den fda entscheid excellagen ist schnell verpufft.
sieht so aus, beide produkte excellagen sowie generex (noch?) nicht markt entdeckt worden sind.

CXM muss jetzt beweisen, ob sie einen starken partner für excellagen finden und ob generex in russland funktioniert.

cash haben sie wieder in der kasse.

ich glaube die besten monate haben wir jetzt vor uns...

wie ist deine einschätzung?

gruss

[asics01]

Antwort auf Beitrag Nr.: 42.368.451 von Ahorne am 18.11.11 11:07:26

hallo

man findet momentan nichts brauchbares was einem weiterhilft sprich
wie gut ist excellagen gegenüber anderen produkten,was bringt excellagen im jahr an umsatz.........
das werden wir wohl erst nach einer verpartnerung erfahren,und das kann wohl nicht mehr lange dauern,wenn die excellagen in Q1.2012 gross vermarkten wollen
bin übrigens bei 0.39$ wieder eingestiegen

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.369.182 von asics01 am 18.11.11 13:13:28

das werden wir wohl erst nach einer verpartnerung erfahren,und das kann wohl nicht mehr lange dauern,wenn die excellagen in Q1.2012 gross vermarkten wollen

Ja, so sehe ich das auch... hoffe auch bald mehr über generex zu erfahren.

schöner Einstandkurs hast Du

meiner ist 0.50 & 0.40 $

gruss

[asics01]

hallo ahorne

weisst du wie es mit dem patentschutz von excellagen steht????

asics

[asics01]

hallo ahorne

weisst du wie es mit dem patentschutz von excellagen steht????

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.372.282 von asics01 am 19.11.11 09:04:55

hallo asics

so viel ich weiss nicht:

hier noch eine Antwort auf Übersee:
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

Re: has Excellagen a patent?
Not yet, but I would not be surprised to see “patent pending” on the box when they start selling it.

DYODD

[Ahorne]

News on Transdel? Das Gericht wird bald entscheiden, ob Teile von Transdel an CXM übergehen, oder ob ein grosser Kapitalgeber von Transdel; die Company "retten/neu-organisieren" darf...

hier noch ein gutes Posting aus dem yahoo Forum:
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

CXM: Cardium. News on Transdel?
20-Nov-11

CXM had a deal to buy the valuable assets of Transdel Pharma.

Transdel is in bankruptcy and CXM had made quite a nice deal to upload some of their prime assets, but its been held up by other creditors of Transdel.

Imo, CXM is going to pop quite nicely for any numbers of reasons.

The Transdel deal might be one that few have really expected at this point.


"During third quarter 2011, the Company announced plans to acquire substantially all of Transdel Pharmaceuticals' business assets in connection with a proposed asset purchase with expedited review under Section 363 of the Bankruptcy Code. Transdel's major creditor had filed a declaration in favor of Cardium's proposed purchase, but subsequently opposed the sale, potentially to offer a plan of its own, which led to the court denying Transdel's motion for expedited approval of a sale to Cardium. Cardium is continuing to evaluate its options with respect to the Transdel transaction and other business opportunities, consistent with the Company's long-term business strategy."


NOTE: Court docket is for Monday, Nov. 21, 2011 @ 3pm. If nothing else it may cause some antsy sideliners to step back in and buy back CXM.

http://www.casb.uscourts.gov/Calendars/BOWIE/1mon.pdf

[asics01]

Cardium Announces First International Marketing and Distribution Agreement for Commercialization of Excellagen™ in South Korea







SAN DIEGO, Jan. 5, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it has entered into its first international agreement for the commercialization of Excellagen™ in the South Korean market. Cardium entered into a marketing and distribution agreement with BL&H Co. Ltd., an established pharmaceutical company based in Korea, for the commercialization of Excellagen Formulated Fibrillar Collagen Gel in the South Korean market under a transfer price arrangement as further described below.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

"With our successful regulatory clearance of Excellagen by the FDA, and production of commercial supplies in process, we look forward to initiating commercialization of Excellagen with strategic and distribution partners having access to podiatrists and other wound care specialists," stated Christopher J. Reinhard, Chairman and CEO of Cardium Therapeutics. "In that regard, we are pleased to announce the first of what we plan to be a series of marketing and distribution agreements with commercialization partners in the U.S. and other markets consistent with Cardium's business model."




Under the BL&H agreement, Cardium will manufacture and supply Excellagen to BL&H at an up-front transfer price which will be 40% of the sales price based on reimbursement pricing to be established for the South Korean market. BL&H will be responsible for all costs related to regulatory filings, as well as sales, marketing and distribution activities. The Korea Food and Drug Administration registration process is adaptive to products that have received U.S. FDA clearance and the registration and reimbursement pricing process can typically be completed within about a year from application. As part of the regulatory process in Korea, BL&H plans to provide the health authorities with the findings of Cardium's Matrix clinical study, which showed that formulated collagen can significantly accelerate reductions in wound radius immediately following application compared to standard of care therapy in diabetic foot ulcers, and can support platelet activation and release of the wound healing protein, Platelet-Derived Growth Factor (PDGF). These findings were published in the peer-reviewed official journal of the Wound Healing Society, Wound Repair and Regeneration, (2011) 19: 302-308, available at www.cardiumthx.com/pdf/ExcellagenPaper_WoundRepair.pdf.


About Excellagen™ Formulated Fibrillar Collagen Gel

Cardium recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell its Excellagen™ professional-use, sterile, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds. Excellagen is a highly-refined fibrillar flowable bovine collagen topical gel (2.6%) intended to support a favorable wound healing environment. Excellagen is intended for use at one- to two-week intervals following surgical debridement (with weekly outer dressing changes) and will initially be supplied in the form of a kit consisting of four sterile, pre-filled, ready to use single-use syringes, each containing 0.5 cc of Excellagen formulated collagen topical gel (2.6%), and four sterile flexible applicators to facilitate topical administration to the wound site over a course of up to four treatments. Detailed information about Excellagen, including the product's directions for use, is available at www.excellagen.com and the investor presentation can be accessed at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-pre… An informational video, Excellagen: A New Wound Care Pathway, is available at http://www.youtube.com/watch?v=D2GYCYc_8JE.

About BL&H Co. Ltd.

BL&H Co. Ltd. is a privately-owned pharmaceutical company based in South Korea. BL&H was established in 1999 with the aim of becoming a leader in the delivery of pharmaceuticals and services that fulfill unmet medical needs in the Korean market. The management team has extensive experience in the pharmaceutical and healthcare sectors and in bringing specialty products to market.

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform. The Company's lead commercial product Excellagen™ topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that we can successfully introduce Excellagen into wound care markets for the treatment of diabetic foot ulcers or other dermal wounds; that Excellagen will be approved for commercialization in Korea or other international markets and sufficiently reimbursed; that we can have Excellagen or our other products manufactured in a successful and cost-effective manner; that we can attract suitable commercialization partners for our products or that such partners will successfully commercialize our products; that our exchange listing compliance can be reestablished and maintained; that our product or product candidates will not be unfavorably compared to other competitive products that may be regarded as safer, more effective, easier to use or less expensive; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures or in actual use; that clinical studies and regulatory clearances even if successful will lead to product advancement or partnering; that that FDA or other regulatory clearances or other certifications, or other commercialization efforts will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; that new collaborative partners will be found; that additional product opportunities will be established; or that that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™, and Nutra-Apps™, Neo-Energy™, and Neo-Carb Bloc™ are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.

(Other trademarks belong to their respective owners)




SOURCE Cardium Therapeutics




Latest "In Focus" News Stories

Consumer boycott power and the new web
Dec 27, 2011

Payroll tax 'compromise' builds uncertainty.
Dec 23, 2011

Fresh tensions unsettle the Falklands
Dec 22, 2011

Court sides with Apple against HTC in UI patent dispute
Dec 20, 2011

Extra capital requirements hammer bank stocks
Dec 19, 2011




NASDAQ OMX
About NASDAQ OMX

NASDAQ OMX Technology

Nasdaq OMX Listing Center

Investor Relations

Public Policy Advocacy
NASDAQ.com
Join Our Community

Sitemap

Advertise With Us

Link to Us

Feedback
Stay Connected
The latest from @NASDAQ:

NASDAQ.com
NASDAQ
NASDAQ $HTLD upgraded from Underperform to Sector Perform bit.ly/bbuT7e #nasdaq 31 minutes ago · reply · retweet · favorite
Join the conversation
Browse The Financial Glossary: 123 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Search the site: NASDAQ.com only Web Search Local Search
Company List | Copyright | Disclaimer | Trademarks | Privacy Statements | Contact Annual Reports | Careers | Custom Logo Ticker | NASDAQ Toolbar Qfolio for the iPhone | Qfolio HD for the iPad | Qfolio for the Blackberry Playbook Tablet

Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

[Ahorne]

Antwort auf Beitrag Nr.: 42.555.107 von asics01 am 05.01.12 16:33:23

Ein guter Anfang - jetzt noch ein paar grössere Märkte wäre nicht schlecht

[asics01]

Antwort auf Beitrag Nr.: 42.555.427 von Ahorne am 05.01.12 17:19:39

als nächstes ist amerika dran

[Ahorne]

Antwort auf Beitrag Nr.: 42.555.543 von asics01 am 05.01.12 17:37:26

denkst du mit Partner oder im Alleingang?

cu

[Ahorne]

Antwort auf Beitrag Nr.: 42.555.107 von asics01 am 05.01.12 16:33:23

hier noch der Partner in Süd Korea: http://www.blnh.co.kr/

[asics01]

Antwort auf Beitrag Nr.: 42.555.554 von Ahorne am 05.01.12 17:38:37

schwierig hier eine prognose abzugeben,was mich wundert ist dass der laden noch nicht geschluckt wurde.
wenn ich hier alleine an generex denke,und das potentiel von excellagen.....
seis drum ich habe mich die letzten wochen nicht rauskegeln lassen,sondern immer dazugekauft
jetzt sollen die shorties mal bluten,denn was da die letzten monate abging war doch nur gewollt

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.555.920 von asics01 am 05.01.12 18:37:11

ja, da hast Du wohl recht, ein Schnäppchen

Generex ist meiner Meinung nach gar nicht im Kurs drin.

Ich hoffe einfach sie suchen sich einen starken Partner Excellagen in den USA. Ein Alleingang würde zimlich sicher nicht gut ankommen.

[asics01]

Antwort auf Beitrag Nr.: 42.555.960 von Ahorne am 05.01.12 18:44:02

meine prognose für januar mindestens 1$,der partner für usa (und eventuell mehr wird kommen)
der chief sagte schon im dezember dass im 1 quartal 2012 excellagen vermarktet wird.
was sich schwer einschätzen lässt ist das potential für excellagen,so wie ich das sehe ist excellagen regranex überlegen
aber was gibt es sonst noch an aktuellen konkurenzprodukten????

asics

[asics01]

Antwort auf Beitrag Nr.: 42.555.960 von Ahorne am 05.01.12 18:44:02

Ich hoffe einfach sie suchen sich einen starken Partner in den USA

wie wäre es mit NOVARTIS ???(mein tip)

[asics01]

Antwort auf Beitrag Nr.: 42.556.005 von asics01 am 05.01.12 18:52:42

das dreckspack drückt schon wieder,aber das ist erst das vorspiel,der orgasmus kommt noch

[Ahorne]

Antwort auf Beitrag Nr.: 42.556.410 von asics01 am 05.01.12 20:05:47

ja, es nervt... aber das wird noch ne schöne Geschichte mit CXM in 2012

[Ahorne]

heute und 12. Dezember stellt sich CXM vor:

http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-cal…

01/09/12 4:00 p.m. PT
Cardium Therapeutics at 2012 Biotech Showcase

01/10/12 11:00 a.m. PT
Cardium Therapeutics at OneMed Forum SF

[Ahorne]

Zitat von Ahorne: heute und 12. Dezember stellt sich CXM vor:

http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-cal…

01/09/12 4:00 p.m. PT
Cardium Therapeutics at 2012 Biotech Showcase

01/10/12 11:00 a.m. PT
Cardium Therapeutics at OneMed Forum SF

natürlich am 12. Januar 2012 (nicht 12 Dezember)

lebe noch in der Adventszeit

[asics01]

Antwort auf Beitrag Nr.: 42.569.753 von Ahorne am 09.01.12 17:55:06

läuft doch prima zur zeit,und die news auf die wir warten (verkaufsstart excellagen,verpartnerung.....) steht uns noch bevor.
die nächsten wochen werden wohl sehr interesant werden.

asics

[Ahorne]

ja, läuft

Can Cardium Therapeutics (AMEX: CXM) Capitalize on FDA Approval and Commercialization Deal During First Quarter 2012?
http://www.otcequity.com/?p=1662#more-1662

[Ahorne]

CXM in Globaldata Jan 2012 Report

who is who & Cardium Theapeutics

http://www.giiresearch.com/report/gd227725-atherosclerosis-o…

Starting from 3,500 USD you can receive a market research report from Globaldata "Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018"

Check out who's name/product/device is included


# Most Promising Drug Profiles 55

* 5.7.1 Anacetrapib (MK- 0859) 55
* 5.7.2 Darapladib 56
* 5.7.3 Dalcetrapib (RG1658) 57
* 5.7.4 Mipomersen 58
* 5.7.5 Varespladib (A-002) 59
* 5.7.6 MK-0524B 60
* 5.7.7 Aleglitazar (RG1439) 61
* 5.7.8 Vorapaxar 62
* 5.7.9 Aliskiren 63
* 5.7.10 Canakinumab (ACZ885) 64
* 5.7.11 Generx 64
* 5.7.12 Cangrelor 65
* 5.7.13 Otamixaban 66
* 5.7.14 Xarelto (rivaroxaban) 67


......

Future Players 78

* 8.1 Introduction 78
* 8.2 Company Profiles 78
o 8.2.1 GlaxoSmithKline Plc 78
o 8.2.2 Merck & Co., Inc. 80
o 8.2.3 F Hoffmann La Roche 82
o 8.2.4 ISIS Pharmaceuticals 82
o 8.2.5 Anthera Pharmaceuticals 83
o 8.2.6 Novartis A G 84
o 8.2.7 Sanofi 85
o 8.2.8 Johnson & Johnson 86
o 8.2.9 Bayer AG 87
o 8.2.10 Cardium Therapeutics 88
o 8.2.11 The Medicines Company 90
o 8.2.12 Tabular Presentation Details of Other Companies in the Pipeline 91
o 8.2.13 Key Takeaway 97

[asics01]

hallo ahorne

als aktionär von cxm braucht man nerven wie drahtseil.
die langen jahre bis zur zulassung,
jetz finden sie wohl keinen partner für excellagen,
und dann diese ewige kursdrückerei
kein wunder dass da manch einer entnervt schmeisst,
generex ist noch weit vom markt entfernt,und garantie dass es wirkt oder zugelassen wird gibt es auch keine.
vielleicht wird doch noch alles gut?????
bist du noch dabei
asics

[Ahorne]

Guten Morgen Asics01

Wie recht doch Du hast!
Nerven braucht man wirklich mit dem Wert. Noch extrem viele Shorties sind drin. Ohne starken US Partner wird meiner Meinung die Spielchen weiter gehen.

generex - wird überhaubt nich wahrgenommen - hoffen wir auf gute Daten vom russischen Programm.

ps. der Südkorea Deal finde ich schon mal ein guter Anfang. Immerhin rund 48 Mio. Einwohner. USA rund 317 Mio. Also so klein ist der Markt in Südkorea nicht, wird aber vermutlich in den USA als klein wahrgenommen.

& ja, ich bin noch drin

[Ahorne]

Top 10 Pharmaceutical Stocks with Highest Upside: DARA, CYTR, EPCT, STEM, ANX, HEB, PATH, NABI, CXM, OCLS (Jan 16, 2012)
http://www.cnanalyst.com/2012/01/top-10-pharmaceutical-stock…

u.a.
Cardium Therapeutics Inc (AMEX:CXM) has the 9th highest upside potential in this segment of the market. Its upside is 322.1%. Its consensus target price is $1.50 based on the average of all estimates.

[Ahorne]

Biotechnology Industry on the Upswing - BioSante and Cardium Therapeutics Look to Rally
http://finance.yahoo.com/news/Biotechnology-Industry-iw-2651…

[asics01]

das liest sich immer alles gut,aber letztendlich hat halt doch der markt recht,wie man die letzten jahre sehen kann.
aus cardium werde ich sowieso nicht schlau,da hat man die zulassung von excellagen,einen partner in südkorea,source one als partner,und generex in phase 3 und eine mk von 34,9 mio??????????

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.606.556 von asics01 am 17.01.12 18:56:41

Schaun wir mal Live Again ist:

On Friday, January 13, 2012, a U.S. federal trademark registration was filed for LIFE AGAIN by Cardium Therapeutics, Inc., San Diego, CA 92130. The USPTO has given the LIFE AGAIN trademark serial number of 85515933.

http://www.trademarkia.com/life-again-85515933.html" target="_blank" rel="nofollow ugc noopener">http://www.trademarkia.com/life-again-85515933.html

[Bullson]

Hallo,

nur das seltsame ist, das dieses LIFE AGAIN unter der Rubrik Insurances läuft ???
Wonanders habe ich gelesen dass wohl in einem Corporate CXM-Video dieses LIFE AGIN mehrfach genannt wurde im Zusammenhang, das geheilte Patienten nun wieder ein lebenswertes Leben haben.....
Aber nix genaues weiß ich nicht.

Bullson

[Ahorne]

Zitat von Bullson: Hallo,

nur das seltsame ist, das dieses LIFE AGAIN unter der Rubrik Insurances läuft ???
Wonanders habe ich gelesen dass wohl in einem Corporate CXM-Video dieses LIFE AGIN mehrfach genannt wurde im Zusammenhang, das geheilte Patienten nun wieder ein lebenswertes Leben haben.....
Aber nix genaues weiß ich nicht.

Bullson

Danke für den Hinweis, Klasse!

Ich habe Generx Video kurz überflogen und evt. was gefunden:

http://www.youtube.com/watch?v=pjUndFhJkjM&feature=email

schau mal 2.19 bis 2.20


ps. das mit Insurances ist schräg, vielleicht ein Fehler.

[asics01]

habe gestern entnervt die hälfte zu 0,39$, mit 21% gewinn geschmissen.der rest folgt beim nächsten anstieg,ich hoffe nur dass es nicht nochmal auf die 0,30$ geht.

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.640.781 von asics01 am 24.01.12 18:12:39

21% netter Gewinn

ja, CXM macht einem das Leben nicht leicht... hoffe Du kommst noch gut raus.

Ich fühle mich derzeit wohl mit CXM.

[asics01]

ich habe bei clsn noch mal aufgestockt,deswegen auch der teilverkauf.
bei cxm läuft wohl einiges unrund,deswegen werde ich beim nächsten anstieg wohl rausgehen,da wird wohl noch einige zeit vergehen bis hier mal was durchgreifendes kommt...

[asics01]

die 0,35$ sind gefallen,jetzt wird es spannend wird wohl doch auf die 0,30$ gehen.
glaubs solangsam das excellagen doch wohl nicht der bringer wird?????
asics

[asics01]

hallo ahorne

bin dann mal weg,wurde heute ausgestoppt bin aber nicht traurig deswegen.jetzt brauch ich mir dieses trauerspiel wenigstens nicht mehr mitanzusehen.
ich hoffe dass ich mit dem rest (exel,astx,csln)mehr glück habe.
ich wünsche dir trotz allem noch steigende kurse,vielleicht komme ich bei 0,30€ noch mal zum zug (sieht wohl danach aus.

[Ahorne]

Hallo asics01

Ich kann Dich gut verstehen. cxm macht es einem nicht leicht.
Nun ist sie bei Dir weg und der Kopf ist frei, schön

Ich gebs ehrlich zu, ich habe ein bisschen ein Narren an cxm gefressen.
Nicht gut, passiert mir auch nicht all zu oft...

Werde mein grosszügiger mentaler Stopp aber schon einhalten.

ich wünsche Dir alles gute mit Deinen anderen Investment und wir werden uns wieder mal über den Weg laufen

[asics01]

Antwort auf Beitrag Nr.: 42.653.360 von Ahorne am 26.01.12 18:13:37

auf was setzt du bei cxm ???
auf excellagen??? (da ist doch schon bei der zulassung wohl einiges daneben gelaufen,jetzt finden sie wohl keinen partner. wieso nicht????
wird wohl so sein, dass excellagen nicht besser wirkt als dass was momentan am markt ist,bzw in nächster zeit kommt
ohne partner,und ohne kohle excellagen vermarkten...??????
generex???(dauert noch ein paar jahre,um vielleicht auf den markt zukommen.
aber kann ja alles anders kommen

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.653.774 von asics01 am 26.01.12 19:15:27

wieso denkst Du das excellagen kein Erfolg sein kann? Südkorea ist schon mal im Boot...

und ja, ich sehe sehr grosses Potential in generex...

Bewertung meiner Ansicht sehr tief.

Risiko ist klar da, Changen aber auch

[asics01]

Antwort auf Beitrag Nr.: 42.653.902 von Ahorne am 26.01.12 19:34:59

die hatten doch schon im vorfeld der zulassung genug zeit sich um einen partner zu bemühen,und jetzt 4 monate nach zulassung immer noch nichts.
noch nicht mal einen termin wann man mit der vermarktung beginnen will,schon alles ein bischen komisch oder???
wenn excellagen so gut sein soll,wo ist das problem???

asics

[asics01]

und ein kurs von 0,34$ (ende offen) spricht doch wohl auch für sich

[Ahorne]

Antwort auf Beitrag Nr.: 42.654.141 von asics01 am 26.01.12 20:16:29

excellagen - der sürkorea deal ist fact! (50 Mio Einwohner), bald werden andere folgen... und in russland beginnt in in Q1 das generex programm

die Zeit wird es uns zeigen ob cxm Erfolg haben wird oder nicht...

[asics01]

Antwort auf Beitrag Nr.: 42.654.376 von Ahorne am 26.01.12 20:49:06

aber nicht vergessen,der zulassungsantrag in südkorea ist eingereicht mehr nicht
die zulassung wann auch immer (ob oder vielleicht)ist noch nicht da

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.654.434 von asics01 am 26.01.12 20:59:30

ich denke es gut das Du raus bist

ja, es gibt diverse Unsicherheiten, das zeigt der Kurs und auch der derzeitige Unternehmenswert.

ps... die FDA hat die Zulassungen erteilt. Das Südkorea dies auch tun wird, ist sehr wahrscheinlich.

[asics01]

aber seis drum,ich mache mir da keinen kopf mehr wieso die zb. für den heimischen wichtigen markt (usa)noch keinen partner haben,
oder nicht sagen können wie und wann sie excellagen vertreiben wollen.
wird wohl nicht auch 2 jahre dauern wie die genehmigung der fda für excellagen.

asics

[Ahorne]

Cardium Presents New Generx Findings at 2012 Annual Gene and Cell Therapy Forum

New insights Support Generx Angiogenic Therapy Phase 3 Registration Clinical Study for Patients with Coronary Artery Disease

http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-new…

[Bullson]

Hallo,

wird mal Zeit für ein paar News, ist schon sehr ruhig um CXM.

Recht aktuell ist nun die Teilnahme an verschiedenen Health Care/Wound Care Conferences im März und April:

siehe link auf die CXM - website:
http://www.excellagen.com/physician-purchase-information.htm…

Bullson

[asics01]

was wollen die den an news rausgeben???dass sie für excellagen keinen partner finden???oder dass sie aus welchem grund auch immer nicht liefern können??
ist excellagen eine totgeburt??????
da wäre ich auch ruhig
in dem laden ist doch einiges oberfaul

[Bullson]

Antwort auf Beitrag Nr.: 42.696.195 von asics01 am 03.02.12 16:44:55

Ich sehe es nicht ganz so negativ.
Sicherlich hast Du recht das Sie für die Vermarktungs/Partner - Thematik schon sehr lange brauchen - ggf gibt es einen oder mehrere Gründe dafür Hoffen wir das mal.

Nur, wenn Sie keinen Fortschritt hätten und deshalb die Klappe halten, dann bräuchten sie auch nicht an den verschiedenen Messen teilnehmen. Und die message dass Sie teilnehmen ist erst vor wenigen Tagen aktualisiert worden
Hoffe natürlich das ich recht habe.. .

Schönes Wochenende

Gruß
Bullson

[asics01]

Antwort auf Beitrag Nr.: 42.696.351 von Bullson am 03.02.12 17:03:57

ich will hier nichts schlecht reden,nur wenn man eins und eins zusammen zählt muss man schon ins grübeln kommen.
die abnormale lange zeit bis zur zulassung von excellagen,dann hatten die doch im vorfeld der zulassung jede zeit der welt um sich schon nach einem partner umzuschauen.
wenn denn excellagen so gut sein soll,wo ist das problem????
die setzen alle hoffnung auf generx (aber das dauert noch ein paar jahre,bis da vielleicht was kommt)und ihre dna datenbank.
und wie du schreibst die infos seitens cxm ,normal muss da doch schon lange die offizielle meldung da sein,dass zb.im märz.....????excellagen zum verkauf bereit steht.
aber nix desgleichen kam bisher,nur schweigen und die shorties nützen das natürlich aus und hauen immer drauf.
auser da wissen ein paar mehr,und der kurs steht zu recht da wo er steht.
aber vielleicht wird auch alles gut
asics

[Ahorne]

Cardium Therapeutics

Phacilitate Cell & Gene Thearpy Forum 2012
http://www.cardiumthx.com/pdf/Generx-Rubanyi-Presentation-01….
Washington DC
January 30, 2012

u.a.

Status:

- Ministry of Health of the Russian Federation Approval of Protocol/Trial

- Study Start: 1Q 2012

[asics01]

Cardium Announces $5.0 Million Financing With Institutional Investors








SAN DIEGO, Feb. 13, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it has entered into definitive agreements with three institutional and accredited investors to sell an aggregate of 17,857,143 shares of its common stock in a registered direct offering for gross proceeds of approximately $5.0 million, before deducting placement agent's fees and estimated offering expenses.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

The investors have agreed to purchase the shares of common stock for a price of $0.28 per share with no warrant coverage. The closing of this offering is expected to occur on or about February 16, 2012, subject to the satisfaction of customary closing conditions. The net proceeds from the offering will be used for general working capital purposes.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE Amex: LTS), acted as the exclusive placement agent for the offering.

The common stock is being offered pursuant to a shelf registration statement that was filed by Cardium Therapeutics with the Securities and Exchange Commission (the "SEC") and declared effective by the SEC on August 27, 2010. A prospectus supplement related to the public offering was filed with the SEC on February 13, 2012. Copies of the prospectus and accompanying prospectus supplement relating to the offering may be obtained from the SEC's web-site at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or by request from Ladenburg Thalmann & Co., Inc, 4400 Biscayne Blvd., 14th Floor, Miami, Florida 33137.



About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform. Cardium's lead commercial product Excellagen™ topical gel for advanced wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.



Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that the registered direct offering can be completed as proposed or that we will not be adversely affected by risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission.





Copyright 2012 Cardium Therapeutics, Inc. All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.









Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™,
Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™, D-Sorb™, Neo-Energy™, Neo-Carb Bloc™, Nutra-Apps™ are trademarks of
Cardium Therapeutics, Inc. or Tissue Repair Company.
(Other trademarks belong to their respective owners)








SOURCE Cardium Therapeutics

Bonnie Ortega, Director, Investor/Public Relations of Cardium Therapeutics, Inc., [phone], [e-mail]









back to top

[Ahorne]

Antwort auf Beitrag Nr.: 42.743.485 von asics01 am 13.02.12 17:19:56

sehr unschön.

Prev Close: 0.37
PP 0.28

[asics01]

wieso zu diesem preis???die bekommen ihr excellagen nicht an den mann.
egal bin heute wieder rein

[Ahorne]

Antwort auf Beitrag Nr.: 42.743.645 von asics01 am 13.02.12 17:46:45

entweder sie bringen excellagen wirklich nicht an den Mann oder sie wollten noch günstig "Freunde" reinlassen. Wäre ja nicht das erste mal, das so was passiert.

Mit CXM macht man ja schon einen durch.

Willkommen in Geisterbahn

[asics01]

Antwort auf Beitrag Nr.: 42.743.565 von Ahorne am 13.02.12 17:32:57

wieso zu diesem preis???,wird wohl doch so sein dass sie keinen partner für excellagen finden,oder sonst irgendwo leichen im keller haben.
egal einen zock ist es wert,bin heute wieder rein

asics

[asics01]

Antwort auf Beitrag Nr.: 42.743.667 von Ahorne am 13.02.12 17:50:12

möglich ist in diesem laden alles,warten wir mal ab was die nächsten wochen passiert.
meine meinung mitte ende märz wissen wir wo es lang geht,oder ob überhaupt noch irgendwas geht

asics

[Ahorne]

Cardium Announces Closing of $5.0 Million Equity Financing
http://finance.yahoo.com/news/Cardium-Announces-Closing-5-0-…
Press Release: Cardium Therapeutics.

[asics01]

excellagen war und ist wohl eine fehlgeburt,(das fing schon im vorfeld der 2 jährigen zulassung an)was den laden wohl am leben hält ist die hoffnung auf generex.

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.761.659 von asics01 am 16.02.12 16:46:26

warten wir ab:
Cardium's lead commercial product Excellagen™ topical gel for advanced wound care management, has recently received FDA clearance for marketing and sale in the United States.

& von generex ist sehr intressant.

[asics01]

Cardium's lead commercial product Excellagen™ topical gel for advanced wound care management, has recently received FDA clearance for marketing and sale in the United States

und wenn es keiner kauft???wieso steht der kurs bei 0,28$,wenn doch alles so gut sein soll???
geht doch schon monate (jahre)ein schritt vor,zwei schritte zurück.
glaube mir die 0,28$ halten nicht ,da geht es noch weiter runter.

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.762.242 von asics01 am 16.02.12 17:58:00

und du wieder mitdabei - brauchst wohl den Nervenkitzel

[asics01]

damit du hier nicht so alleine leiden musst,bin ich wieder an deiner seite.
geteiltes leid ist halbes leid

hab ich doch geschrieben dass ich nach bekannntgabe der finanzierung
wieder rein bin.habe ein paar zu 0,29 gekauft,und gerade noch mal zu 0,2845$

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.762.369 von asics01 am 16.02.12 18:18:25

Du bist aber lieb

letztes Jahr CXM mit minus 20% Verkauf. dieses Jahr bei 0.31 USD gekauft; war schön im Plus, betonung auf war. Entweder Hartnäckig oder Dumm.

[asics01]

Antwort auf Beitrag Nr.: 42.762.488 von Ahorne am 16.02.12 18:33:20

entweder geht sie vollends wieder den bach runter(0,15-0,20$)oder es kommen mal richtig gute news (auf die warte ich schon lange),und die ewige kursdrückerei hört auf
glück auf

asics

[asics01]

Antwort auf Beitrag Nr.: 42.763.040 von asics01 am 16.02.12 19:44:42

Entweder Hartnäckig oder Dumm.

ahorne nicht böse sein,aber ich tippe auf dumm (betifft mich natürlich auch)

[asics01]

nichts neues, alles beim alten, es geht weiter abwärts

[asics01]

Antwort auf Beitrag Nr.: 42.768.401 von asics01 am 17.02.12 16:09:13

wow,jetzt sind wir schon bei 0,27$ angekommen,wenn die in diesem tempo so weiter fällt ist sie in 1-2 wochen wieder bei 0,13$

[asics01]

Antwort auf Beitrag Nr.: 42.790.775 von asics01 am 22.02.12 18:42:43

Cardium Partners With NPI, InHealth Media





DELRAY BEACH, Fla., March 14, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) is now making its MedPodium Nutra-Apps® products available across the United States by working with Nutritional Products International (NPI) and InHealth Media.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

Nutra-Apps are easy-to-use dietary supplements designed to promote personal health and well being for today's active professionals. NPI distributes the company's products to retail and online outlets across the U.S., while InHealth Media is responsible for the marketing of the MedPodium brand.

"We are very excited to work with both NPI and InHealth Media to not only expand the distribution of our products, but also to increase our brand awareness with Millennials, who love to discover new brands," said Hanna Wagari, Director of Marketing. "Our Nutra-Apps are designed to fuel the active lifestyle of modern consumers, and we are proud to offer them throughout the United States."

MedPodium Nutra-Apps are designed to have a pharmaceutical-like touch and feel that consumers seek. The capsules are small, sealed and come in one-and-done dosing. All of the products feature standardized and scientifically validated ingredients at the clinically studied amounts for efficacy. The packaging is designed to comfortably fit in a pocket or purse for use anytime and anywhere.

Nutra-Apps' Neo-Carb Bloc® for weight management and Neo-Energy® for enhanced performance are packaged as "impulse buy" counter items for on-the-go consumers with completely spontaneous lifestyles. The packaging is bright, fun and eye-catching to help it stand out on store shelves.

"With its innovative Nutra-Apps, MedPodium offers convenience and value to consumers all across the United States," said Brian Gould, Director of Operations for NPI. "We are thrilled to launch this line in the American market, and expect great things from the brand in the near future."

NPI (http://www.nutricompany.com/) is a nutraceutical and cosmoceutical firm that provides sales and distribution services for worldwide brands. It specializes in working with key buyers across the U.S., providing a fast track to the world's most important market.

InHealth Media (http://www.inhealthmedia.com/) provides comprehensive and strategic media services for sporting goods companies, sports media firms and organizations that manufacture sports nutrition, nutraceutical, functional foods, functional beverage and personal care brands, among many others

To learn more about MedPodium, please visit http://www.medpodium.com/ and view the Nutra-Apps video at http://www.youtube.com/watch?v=BtGqfI0Vfvs.

SOURCE Cardium Therapeutics; Nutritional Products International; InHealth Media

Brian Gould, [phone], [e-mail]

da wartest du monate lang auf die eine meldung,und dann kommt das hier (hammermeldung),und sonst nix.
naja irgendwie muss man sich die leute ja bei der stange halten.ich hatte heute trotzdem glück,und konnte meine teile bei 0,2897$ raushauen.
verarsche hoch 10 hier alles.ami biotech halt.

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.902.083 von asics01 am 14.03.12 19:18:28

hier noch der Link:
http://www.theglobeandmail.com/globe-investor/news-sources/?…

immer noch dabei? Du musst ja leiden

[asics01]

Antwort auf Beitrag Nr.: 42.902.188 von Ahorne am 14.03.12 19:35:25

immer noch dabei? Du musst ja leiden

nöö nicht mehr,habe doch heute bei 0,2897 geschmissen

ich schaue mal in einem jahr wieder vorbei,mal schauen ob sie dann mal die 0,30$ genommen hat.



asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.902.324 von asics01 am 14.03.12 19:57:28

man liest sich

Alles Gute, wir werden uns bestimmt irgendwo bei w/o wieder über den Weg laufen.

cheers

[asics01]

Antwort auf Beitrag Nr.: 42.902.430 von Ahorne am 14.03.12 20:12:47

viel erfolg,und weiterhin gute nerven(die brauchst du wohl)mit cxm.
heute geht es nach dieser hammermeldung aber erst mal wieder kräftig bergab.
aber das bist du ja inzwischen wohl gewohnt.

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.902.743 von asics01 am 14.03.12 21:10:09

Meldung ist ja nicht so übel... aber nicht was die Investoren hören wollen.
Na ja, es sollten noch 2 News in Kürze kommen.

schaun wir mal

[Ahorne]

Cardium Initiates Generx® Phase 3 Clinical Registration Study
Study to Evaluate Generx® (Ad5FGF-4) DNA-based Angiogenic Drug Candidate for the Potential Treatment of Myocardial Ischemia Due to Coronary Artery Disease

http://finance.yahoo.com/news/cardium-initiates-generx-phase….

[asics01]

kurs 0,277$

[Ahorne]

Zitat von asics01: immer noch dabei? Du musst ja leiden

nöö nicht mehr,habe doch heute bei 0,2897 geschmissen

ich schaue mal in einem jahr wieder vorbei,mal schauen ob sie dann mal die 0,30$ genommen hat.

Dein Jahr war aber kurz... ich sehe, CXM lässt Dich nicht los



asics

[asics01]

Antwort auf Beitrag Nr.: 42.930.034 von Ahorne am 20.03.12 16:46:19

hallo

ich kriege noch den newsletter von cxm,deswegen immer am ball.
sag mal geht dir diese kursdrückerei nicht so langsam auf den zeiger?????
du musst schon nerven wie dahtseil haben,aber vielleicht wird dein durchhaltevermögen irgendwann belohnt.
ich gönne und wünsche es dir??

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.930.073 von asics01 am 20.03.12 16:52:45

Hallo asics

Ich finde es ja toll, das Du hier bist
Sonst wäre es ja zu langeweilig bei diesem Thread.

Ich handle den grössten Teil meines Depot mittels einesn Börsenbrief mit sehr sehr spekulativen Aktien. Frag nicht nach dem Namen

Daher bin ich mir einige Einschläge aber Runs gewohnt. CXM ist wirklich ne Hartnäckig Nuss - ich glaube einfach an die Story und bin Stur.

Du hast schon recht - Hartnäckig oder (das sag jetzt ich: Dumm)

[asics01]

Antwort auf Beitrag Nr.: 42.930.754 von Ahorne am 20.03.12 18:22:24

und jetzt lache (oder auch nicht),ich bin die letzten tage auch wieder bei 0,273 und 0,275$ rein.
hier kriegste auch jeder tag die möglichkeit wieder billiger reinzugehen.
das ist doch hardcore oder??:
ich will bei der ernte auch dabei sein

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.930.903 von asics01 am 20.03.12 18:45:51

Du hast recht - ein selter doofer Wert
Solange man noch Schlafen kann - ist alles ok

[Ahorne]

Antwort auf Beitrag Nr.: 42.930.903 von asics01 am 20.03.12 18:45:51

ps. die heutige News finde ich Klasse - der Markt nicht - bin glaube schon verblendet...

[Ahorne]

hier mal der Chart: http://stockcharts.com/h-sc/ui?s=cxm

[asics01]

hammerhart der chart

[Ahorne]

RevNutrition.com to Carry MedPodium Nutra-Apps® Brand
http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-new….

[asics01]

die sollen lieber mal berichten was mit excellagen sache ist.

[Ahorne]

Antwort auf Beitrag Nr.: 42.936.201 von asics01 am 21.03.12 16:24:33

News über Verkauf sollte noch diesen Monat kommen.
Vermutlich zunächst Alleingang.

[asics01]

Antwort auf Beitrag Nr.: 42.936.578 von Ahorne am 21.03.12 17:19:29

News über Verkauf sollte noch diesen Monat kommen.
Vermutlich zunächst Alleingang

WISSEN oder HOFFEN ??????

[Ahorne]

Zitat von asics01: News über Verkauf sollte noch diesen Monat kommen.
Vermutlich zunächst Alleingang

WISSEN oder HOFFEN ??????

Aussage von der Company. Verkauf soll in Q1. 2012 starten...

[asics01]

Antwort auf Beitrag Nr.: 42.937.701 von Ahorne am 21.03.12 19:56:40

das sagte der ceo vor ein paar monaten,und wenn doch nicht???
alleingang dann dümpelt der kurs noch ein weilchen um die 0,28-0,30$,die shorties haben den kurs im griff.
da sie wohl doch keinen partner finden, ist excellagen wohl auch nicht gross gefragt, oder die wirkung gegenüber regranex oder sonstigen produkten gleich.

asics

[Ahorne]

Antwort auf Beitrag Nr.: 42.938.018 von asics01 am 21.03.12 20:51:29

da muss ich Dir widersprechen. Company hat nie gesagt, dass excellagen vor Q1 verkauft wird. ob excellagen ein Erfolg wird weiss ich nicht. Und ja, die Shortis sind derzeit am Drücker.

[asics01]

Antwort auf Beitrag Nr.: 42.938.308 von Ahorne am 21.03.12 21:58:45

der ceo sagte vor ein paar monatan,dass excellagen in Q1 vermarktet werden soll.
egal news um news, kurs heute 0,2781$ und dass zählt.das wird in naher zukunft nichts werden, auser es kommen hammernews.
aber woher sollen die kommen ???
da wird wohl noch die eine oder andere ke folgen (generex ph 3,und vermarktung excellagen kosten geld, excellagen wird wohl nicht viel an umsatz bringen)
aber zu welchem preis und wann???

asics

[asics01]

Antwort auf Beitrag Nr.: 42.938.363 von asics01 am 21.03.12 22:23:43

habe meine teile heute wieder zu 0,2840$ rausgehauen.wieder ein paar euros gemacht.
die kriegt man nächste woche wieder für 0,27$ oder billiger, weil die im 1. quartal nichts mehr gebacken kriegen

asics

[Ahorne]

Cardium Announces U.S. Market Introduction of Excellagen™

Company also Announces Smith Medical Partners as Logistics Partner for National Distribution of Excellagen™

http://finance.yahoo.com/news/cardium-announces-u-market-int…


SAN DIEGO, March 30, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced market introduction of its Excellagen™ professional-use, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds.

(Photo: http://photos.prnewswire.com/prnh/20120330/LA79308)

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

Excellagen is a new, FDA-cleared highly-refined fibrillar collagen-based topical gel (2.6%) designed to support favorable wound care management. Excellagen's unique high molecular weight bovine Type I collagen formulation is topically applied through easy-to-control, pre-filled, single use syringes. Excellagen is intended for physician use following surgical debridement procedures, and is engineered to support a favorable wound healing environment for non-healing lower extremity ulcers in diabetic patients. Excellagen's viscosity optimized biocompatible gel formulation requires application at only one or two week intervals. It is recommended that Excellagen be applied following surgical debridement in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.

Cardium's market research indicates that physicians seek easy-to-use products to reduce preparation time and facilitate product application - and Excellagen's unique, ready-to-use syringe-based collagen gel requires no thawing or mixing. Because of its specialized formulation, only a thin layer needs to be applied over the wound area, and one syringe containing 0.5 cc of Excellagen covers wounds up to 5cm(2) in size using the supplied 24-gauge sterile, single-use flexible applicator tip. To learn more about new Excellagen and for product ordering information, please visit www.excellagen.com and view the informational YouTube video, Excellagen: A New Wound Care Pathway for Diabetic Foot Ulcers, at http://www.youtube.com/watch?v=D2GYCYc_8JE.

The Company also announced a logistics and cold chain services agreement with Smith Medical Partners, a subsidiary of H. D. Smith focused on specialty distribution of specialty, brand and generic pharmaceuticals, vaccines, injectables and medical/surgical materials. Smith Medical Partners provides practitioners with valuable product insights, information about patient assistant programs and can provide next-day delivery to all 50 states, allowing physicians and wound care clinics to receive Excellagen swiftly and reliably. Additional information about Smith Medical Partners can be found at http://www.smpspecialty.com/.

Initially, the Company's marketing efforts will be centered on web-based marketing and supported by the new unilateral logistics capabilities of Smith Medical Partners. Cardium also plans to present and exhibit at medical trade shows, provide a website physician locator, build a network of key opinion leaders, create patient assistant programs and additional sales and marketing programs. The Company is currently exhibiting Excellagen at the APWCA 2012 Meeting in Orlando, Florida and will be exhibiting at the upcoming SAWC Symposium on Advanced Wound Care Meeting, April 19-22, 2012 in Atlanta, Georgia. Consistent with Cardium's business strategy (similar to the business strategy for the Company's InnerCool operating unit, which was sold to Philips Electronics), Cardium does not plan to establish an internal sales force, and following Excellagen's initial market introduction, will look to strategic partners in the U.S., as well as internationally. In line with this strategy, in January 2012, the Company announced an agreement for the sale and distribution of Excellagen in South Korea, which represents the first of what the Company plans to be a series of marketing and distribution agreements with commercialization partners in the U.S. and other markets.

"We are pleased to announce the market introduction of Excellagen, which is an important milestone for the Company. Following initial market introduction, we look forward to advancing the commercialization of Excellagen in the U.S. and into international markets with strategic and distribution partners having access to podiatrists and other wound care specialists," stated Christopher J. Reinhard, Chairman and CEO of Cardium Therapeutics. "We are also pleased to announce our logistics agreement with Smith Medical Partners, a subsidiary of H. D. Smith and one of the leading national specialty distributors with strong logistics and cold chain capabilities, to provide exceptional ordering and customer support, inventory control and shipping logistics."

Based on Excellagen's technology platform, Cardium plans to conduct post-clearance clinical studies to confirm findings from the formulated collagen Matrix clinical study, consider product line extensions, and pursue therapeutic claims for the treatment of non-healing diabetic foot and pressure ulcers, as well as other wounds. Cardium's Excellagen fibrillar collagen topical gel also represents a new product platform that allows for the potential development of a portfolio of advanced wound care and therapeutic products. Cardium's Gene Activated Matrix (GAM) technology represents one extension of Cardium's FDA-cleared viscosity optimized, fibrillar collagen-based matrix for the localized topical delivery of agents that could include anti-infectives, antibiotics, peptides, proteins, small molecules, DNA, stem cells, differentiated cells and conditioned cell media.

About Cardium
Cardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform. The Company's lead commercial product Excellagen topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com

[asics01]

Antwort auf Beitrag Nr.: 42.979.850 von Ahorne am 30.03.12 15:08:42

in USA +0,21% jetzt gehts rund

[Ahorne]

Cardium Presents Fourth Quarter and Year-End 2011 Financial Results and Recent Developments
http://www.theglobeandmail.com/globe-investor/news-sources/?…
Friday, March 30, 2012

SAN DIEGO, March 30, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE AMEX: CXM) today presented highlights of financial results for its fourth quarter and fiscal year ended December 31, 2011, and other recent developments and outlook for 2012.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

Highlights of 2011 and Recent Developments

Initiated market introduction of Cardium's new Excellagen? professional-use, high molecular weight formulated collagen topical gel following FDA 510(k) clearance received in fourth quarter 2011;
Entered into first international marketing and sales agreement with BL&H Co. Ltd for the commercialization of Excellagen? in the South Korean market;
Initiated the ASPIRE Phase 3 registration study, a 100-patient randomized and controlled multi-center study to be conducted at up to six leading cardiology centers in Russia, designed to evaluate the therapeutic efficacy of the Company's Generx® (Ad5FGF-4) product candidate in patients with myocardial ischemia due to coronary artery disease;
Developed new Cerex?, to support cognitive function*, Alena?, an all-natural, non-stimulant carbohydrate blocker*, and D-Sorb?, 2000 IUs of Vitamin D3 for MedPodium healthy lifestyle brand;
Completed test marketing of MedPodium Nutra-Apps® Neo-Energy® and Neo-Carb Bloc® products at 400 convenience stores in the Southern and Southwestern U.S. with plans to broaden distribution nationally and into the food, drug and mass markets;
Partnered with Nutritional Productions International (NPI) and InHealth Media to market the MedPodium brand and distribute MedPodium Nutra-Apps to retail and online outlets across the U.S.;
Partnered with SourceOne Global Partners for the joint development and commercialization of customized nutritional supplements, as well as pharmaceuticals and medical foods based on SourceOne's branded ingredients;
During 2011 and first quarter 2012, the Company raised a total $11.0 million net proceeds through a registered direct equity investment by institutional and accredited investors in the first quarter 2012 for net proceeds of $4.6 million, and at-the-market transactions during 2011 and first quarter 2012 for net proceeds totaling $6.4 million; and
Regained compliance with NYSE Amex Exchange listing guidelines.
Outlook for 2012

During 2012, Cardium plans to advance the commercialization of its new Excellagen wound care product through strategic partners in the U.S., as well as internationally; develop new product extensions based on Excellagen's formulated collagen product platform for additional wound healing applications; advance forward with the ASPIRE Generx clinical study at leading medical centers in the Russian Federation for patients with advanced coronary disease; introduce additional product line extensions and broaden national distribution of the Company's MedPodium healthy lifestyle product platform; and continue to identify and evaluate businesses, product opportunities and technologies for potential acquisition on favorable economic terms consistent with the Company's long-term business strategy.

Financial Report

For the fourth quarter ended December 31, 2011, the Company presented a loss from operations of $1.9 million, compared to a $1.5 million loss from operations for the fourth quarter in 2010. The increase in operating loss is mainly attributed to an increase in research and development spending associated with the initiation of the Generx ASPIRE Phase 3 registration study and expenses related to the commercial development of Excellagen and the one-time $244,000 Federal grant received in 2010. Net loss for the fourth quarter ended December 31, 2011 was $2.1 million, or $(0.02) per share, compared to net income of $443,000, or $0.01 per share for the same period in 2010. The decrease in net income during this period was due to a favorable change in fair value of derivative liabilities of $1.5 million recorded in the fourth quarter of 2010 compared to an unfavorable $175,000 recorded in the fourth quarter of 2011 and the one-time gain on the Company's 2010 warrant exchange of $474,000.

For the year ended December 31, 2011, the Company presented a loss from operations of $7.4 million compared to a loss from operations of $6.8 million for the year ended December 31, 2010. Cardium presented a net loss of $7.1 million, or $(0.08) per share, for the year ended December 31, 2011, compared to a net loss of $4.7 million, or $(0.06) per share for the year ended December 31, 2010, the increase in the Company's net loss during this period was due to a favorable change in fair value of derivative liabilities of $1.5 million recorded in 2010 compared to a favorable $283,000 recorded in 2011 and the one-time gain on the Company's 2010 warrant exchange of $474,000.

Research and development costs for the three months ended December 31, 2011 totaled $719,000 and general and administrative expenses were $1.2 million, compared to $443,000 and $1.3 million, respectively, for the same period last year. For the year ended December 31, 2011, research and development expense totaled $2.6 million and general and administrative expenses were $4.8 million, compared to $2.3 million and $4.7 million, respectively, for 2010. The increase in research and development expenses in 2011 was primarily due to increased costs related to the initiation of the Generx ASPIRE Phase 3 Registration study and expenses related to the commercial development of Excellagen.

The change in fair value of derivative liabilities was an unfavorable $175,000 for the three months ended December 31, 2011 and a favorable change of $283,000 for the year ended December 31, 2011, and the Company ended the year with derivative liabilities at December 31, 2011 of $86,000. This non-cash liability represents the fair market value of warrants which were previously issued with down round price protection provisions and therefore recorded as derivative liabilities and the non-cash changes in value are required to be recorded in the income statement quarterly.

Cardium ended the 2011 year with a total of $4.9 million in cash ($4.7 million in cash and $200,000 in restricted cash) compared to $8.1 million in the previous year. For the year ended December 31, 2011, Cardium sold 10.5 million shares of common stock in at-the-market transactions for net proceeds of $4.5 million. The total shares of common stock outstanding at December 31, 2011 were 96.6 million compared to 83.1 million shares of common stock outstanding at December 31, 2010.

During the first quarter 2012, the Company raised an additional $4.6 million in net proceeds through the completion of a registered direct equity financing with three institutional and accredited investors with the issuance of 17.9 million shares of Cardium common stock priced at $0.28 per share with no warrant coverage and through the sale of 5.2 million shares of common stock under at-the-market transactions for net proceeds of $1.9 million.

The Company also indicated that the audit opinion accompanying its consolidated financial statements for the year ended December 31, 2011, would again contain a going concern qualification from its independent registered public accounting firm, Marcum LLP. Consistent with its business strategy and as outlined in this press release, Cardium plans to raise additional funds through the strategic sale or monetization of its operating units, entering into strategic licensing agreements, through the future sales of Excellagen, sales of its MedPodium products, and/or other financing transactions.

Excellagen Commercialization Plans

Cardium received FDA 510(k) clearance for marketing and sales in the U.S. of its Excellagen? professional-use, sterile, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds in fourth quarter 2011. The Company recently announced the U.S. introduction of Excellagen and a logistics and cold chain agreement with Smith Medical Partners. Cardium's new and unique Excellagen product is a high molecular weight, sterile, professional use, Type-I bovine collagen topical gel supplied in ready-to-use, prefilled, single-use syringes. Excellagen is intended for physician use following surgical debridement procedures, and is engineered to support a favorable wound healing environment for non-healing lower extremity ulcers in diabetic patients. Excellagen's viscosity optimized biocompatible gel formulation requires application at only one or two week intervals. It is recommended that Excellagen be applied following surgical debridement in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors. Cardium's market research indicates that physicians seek easy-to-use products to reduce preparation time and facilitate product application, and Excellagen's syringe-based collagen gel requires no thawing or mixing. Because of its specialized formulation, only a thin layer needs to be applied over the wound area, and one syringe containing 0.5 cc of Excellagen covers wounds up to 5 cm(2) in size using the supplied 24-gauge sterile, single-use flexible applicator tip.

Initially, the Company's marketing efforts will be focused on targeted e-marketing and supported by the new unilateral logistics capabilities of Smith Medical Partners. Cardium also plans to present and exhibit at medical trade shows, provide a website physician locator, build a network of key opinion leaders, and additional sales and marketing programs. The Company plans to exhibit Excellagen at upcoming medical meetings including the APWCA (American Professional Wound Care Association) 2012 Meeting, March 29 - April 1, 2012 in Orlando, Florida; and the SAWC Symposium on Advanced Wound Care Meeting, April 19-22, 2012 in Atlanta, Georgia. Consistent with Cardium's business strategy (and similar to the business strategy for the Company's InnerCool operating unit, which was sold to Philips Electronics), Cardium does not plan to establish an extensive sales force, but rather, following Excellagen's initial market introduction, to look to strategic commercialization partners with existing sales and marketing forces in the U.S., as well as internationally. In line with this strategy, in January 2012, the Company announced an agreement for the sale and distribution of Excellagen in South Korea, which represents the first of what Cardium plans to be a series of marketing and distribution agreements with commercialization partners in the U.S. and other markets.

To learn more about Excellagen and for product ordering information, please visit http://www.excellagen.com and view the informational video, Excellagen: A New Wound Care Pathway for Diabetic Foot Ulcers, at http://www.youtube.com/watch?v=D2GYCYc_8JE.

Generx Commercial Development Plans

Cardium recently announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of its lead product candidate, Generx® (Ad5FGF-4) in patients with myocardial ischemia due to coronary artery disease. The ASPIRE study, a 100-patient, randomized and controlled multi-center study to be conducted at up to six leading cardiology centers in the Russian Federation, is designed to further evaluate the safety and effectiveness of Cardium's Generx DNA-based angiogenic product candidate, which has already been tested in clinical studies involving 650 patients at more than one hundred medical centers in the U.S., Europe and elsewhere. The efficacy of Generx will be quantitatively assessed using rest and stress SPECT myocardial imaging (Single-Photon Emission Computed Tomography) to sensitively measure improvements in microvascular cardiac perfusion following a one-time, non-surgical, catheter-based administration of Generx.

The Cedars-Sinai Medical Center Nuclear Cardiology Core Laboratory in Los Angeles, California, will serve as the central core lab for the ASPIRE study and will be responsible for the analysis of SPECT myocardial imaging data electronically transmitted from the Russian medical centers participating in the ASPIRE study. Advanced Biosciences Research, an affiliate of bioRASI which is a global clinical research organization, is Cardium's Russian sponsor and development partner and is responsible for the ASPIRE program management and regulatory compliance.

Generx is a disease-modifying regenerative medicine biologic that is being developed to offer a one-time, non-surgical option for the treatment of myocardial ischemia in patients with stable angina due to coronary artery disease, who might otherwise require surgical and mechanical interventions like coronary artery by-pass surgery or balloon angioplasty and stents. Like surgical/mechanical revascularization approaches, the goal of Cardium's Generx product candidate is to improve critical blood flow to the heart muscle ? but to do so non-surgically, following a single administration from a standard cardiac infusion catheter.

The ASPIRE trial represents the fifth clinical study under Generx's clinical development program that when completed will have enrolled more than 750 patients at over 100 medical centers throughout the U.S., Canada, South America, Western Europe and Russia. With positive safety and efficacy data from this single registration study, a Generx registration dossier would become eligible for submission for marketing and sales in the Russian Federation, and would support submissions seeking approval for marketing and sales of Generx in certain other countries of the Commonwealth of Independent States, comprising former republics under the Soviet Union. The ASPIRE study is also specifically designed to provide additional clinical evidence regarding the safety and effectiveness of Generx that would be useful for optimizing and broadening commercial development pathways in other industrialized countries such as Brazil, India, Europe and the United States.

The ASPIRE study (A Randomized, Controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Ad5FGF-4 Using SPECT Myocardial Perfusion Imaging In Patients With Stable Angina Pectoris) is expected to enroll approximately 100 men and women with myocardial ischemia due to coronary artery disease at up to six leading medical centers in Moscow. The study's primary efficacy endpoint will be the improvement in reversible perfusion defect size as measured by SPECT imaging both at rest and under cardiovascular stress. The Russian Health Authority has assigned Generx the therapeutic drug trade name of Cardionovo? for marketing and sales in Russia. Additional information about the ASPIRE study is available at http://clinicaltrials.gov/ct2/show/NCT01550614?term=cardium&…

Recent data from preclinical research conducted at Emory University provided further support for the apparent safety and effectiveness of Generx as a potential one-time non-surgical approach to the treatment of coronary heart disease. This important study demonstrated that induced transient ischemia, using a standard angioplasty balloon catheter, combined with the intracoronary co-infusion of nitroglycerin, substantially enhanced adenovector-mediated gene expression in the heart. Use of these newly applied gene transfer techniques increased the efficiency of gene transfer in preclinical studies by more than two orders of magnitude (p<0.001). These findings have been incorporated into the protocol for the ASPIRE study and the new data underscore the expected benefit of Cardium's improved adenovector administration methods. Use of combined non-surgical, percutaneous balloon catheter-based delivery with transiently-induced ischemia and nitroglycerin to enhance uptake is expected to lead to improved microvascular circulation in the heart. By increasing gene transfer efficiency, this modified delivery approach allows maximizing targeted expression of FGF-4 protein within the ischemic heart of all treated patients, where the resulting angiogenesis or blood vessel growth can bring about improved blood flow. Traditional interventional approaches such as coronary artery bypass surgery (CABG) or angioplasty and stenting (PCI), not only require invasive and costly surgical procedures but they can only directly target selected vulnerable spots in larger vessels that are susceptible to treatment and reachable through mechanical intervention. The recent data, which were presented at the 2012 Annual Gene and Cell Therapy Forum entitled "ASPIRE Trial: A Phase 3 Pivotal Registration Trial Incorporating Preclinical and Clinical Lessons Learned in the Past Decade," can be viewed at http://www.cardiumthx.com/generx.html.

Additional information about Generx and the ASPIRE study is available in a Company presentation titled, Generx Angiogenic Therapy: Regenerative Medicine for Interventional Cardiology, at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-pre… and by viewing, "Cardium Generx Cardio-Chant" at http://www.youtube.com/watch?v=pjUndFhJkjM.

MedPodium's Healthy Lifestyle Brand

Cardium continued the development of new products for its MedPodium healthy lifestyle brand and Nutra-Apps product portfolio. Products selected for the MedPodium portfolio are expected to be substantiated with scientific data supporting an understanding of the mechanism of action, have well-defined manufacturing standardizations, and allow for easy to use formulation and dosage. The Company expanded its MedPodium portfolio through the introduction Cerex? (Panax quinquefolius/ Cereboost?) to support cognitive function*, Alena? (Phase 2® Extra-Strength and ChromeMate®), an all-natural, non-stimulant carbohydrate blocker*, D-Sorb? 2000 IUs of Vitamin D3 (featuring SourceOne Global Partners' unique VESIsorb® lipid-based delivery, which allows the Vitamin D to become more water soluble, which has been clinically proven to provide increased absorption and bioavailability.*)

During the year, Cardium also announced the launch of its MedPodium Nutra-Apps® product line. MedPodium's Neo-Energy® is a dietary supplement capsule that provides a customized blend of natural caffeine, green tea leaf extract and Vitamin B3 (Niacin). Each of Neo-Energy's small, easy-to-use capsules provides an amount of caffeine comparable to commonly-sold energy shots or a premium coffee, or multiple cans (about 20 ounces) of various energy drinks. A pocket-sized pack containing four Neo-Energy capsules will be sold for approximately the same retail price as a single liquid energy shot or beverage. In addition, Neo-Energy capsules have no sugar, no calories, and no aftertaste as commonly found in various drinks.*

MedPodium's new Neo-Carb Bloc® is a dietary supplement that features a custom formulation of maximum strength Phase 2?, a white kidney bean extract that has been clinically studied and shown to reduce the enzymatic digestion of dietary starches contained in many carbohydrate-rich foods such as pastas, rice, crackers, breads, pastries, potato chips, and donuts.* Sold in convenient, pocket-sized packages of two small, easy-use capsules, Neo-Carb Bloc® is designed to selectively reduce the uptake of the types of carbohydrates found in many starchy foods, without blocking the absorption of "good" simple carbohydrates such as those derived from vegetables and whole grains.*

MedPodium's Neo-Energy and Neo-Carb Bloc are currently available at approximately 400 test convenience stores in the Southern and Southwestern U.S. and the Company plans to expand the Nutra-Apps product portfolio with the addition of other product offerings, and to broaden distribution nationally into the food, drug and mass markets. The Company recently partnered with Nutritional Productions International (NPI) and InHealth Media to market the MedPodium brand and distribute Nutra-Apps products to retail and online outlets across the U.S. For information about MedPodium's healthy lifestyle products, please visit www.medpodium.com. A new Nutra-Apps video, "Nutra-Apps: Fuel your Lifestyle", is at http://www.youtube.com/watch?v=BtGqfI0Vfvs.

Financial Highlights

In early 2012, Cardium reported that it had received notice from NYSE Regulation that the Company is now considered to have resolved the listing deficiencies referenced in the NYSE Amex LLC's letter dated November 26, 2010, as previously reported, and that it had regained compliance with the corresponding requirements of the Exchange. The Exchange indicated that as with all listed issuers, the Company's continued listing eligibility will continue to be assessed on an ongoing basis and that the Company is subject to the provisions of Section 1009(h) of the NYSE Amex Company Guide, which may be accessed at www.nyse.com/regulation.

In 2011 and first quarter 2012, the Company completed a registered direct equity financing with three institutional and accredited investors for net proceeds of approximately $4.6 million, after deducting placement agent's fees and estimated offering expenses. The investors purchased an aggregate of 17.9 million shares of the Company's common stock for a price of $0.28 per share with no warrant coverage. In addition, during 2011 and the first quarter 2012, the Company sold 15.7 million shares of common stock in at the-market transactions for net proceeds of $6.4 million.

During the year, Cardium entered into a cross-strategic equity investment with SourceOne Global Partners, for the joint development and commercialization of customized nutritional supplements, as well as pharmaceuticals and medical foods based on SourceOne's branded ingredients.

The Company announced plans to acquire substantially all of Transdel Pharmaceuticals' business assets in connection with a proposed asset purchase with expedited review under Section 363 of the Bankruptcy Code. Transdel's major creditor had filed a declaration in favor of Cardium's proposed purchase, but subsequently opposed the sale, potentially to offer a plan of its own, which led to the court denying Transdel's motion for expedited review. Cardium is continuing to evaluate its options with respect to the Transdel transaction, including its rights to a $500,000 "break-up fee" plus certain expenses and costs that were provided in the asset purchase agreement. Cardium continues to identify and evaluate other companies and businesses, as well as licenses covering product opportunities and technologies to acquire on favorable economic terms consistent with its long-term business strategy.

About Cardium
Cardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform. The Company's lead commercial product Excellagen? topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

[asics01]

das war die meldung,auf die alle so lange gewartet haben, wenn sich nach so einer news der kurs nicht bewegt wann dann?????

[asics01]

habe heute auch den newsletter abbestellt,denn dieses teil ist nur schrott,und wird manipuliert auf teufel komm raus.weiterhin gutes gelingen

asics

[asics01]

Antwort auf Beitrag Nr.: 42.980.456 von asics01 am 30.03.12 16:22:32

zum schluss noch,jetzt wird mir auch klar wieso die ke zu 0,28$.cxm hat auser seinen energie pillen nichts brauchbares zu bieten,(und die gibts von zig anderen anbietern auch,nur halt nicht so poppig verpacktAMEN

[Ahorne]

Antwort auf Beitrag Nr.: 42.980.764 von asics01 am 30.03.12 17:14:07

bye bye...

[asics01]

Ahorne bist du noch dabei,oder hast du heute geschmissen????
das teil wird gerade zerlegt,aktuell 0,27$.
oh mann muss man wieder zulangen,für einen kurzen zock?????
ich habe mal eine kauforder bei 0,2690$ reingelegt


asics

[Ahorne]

Smith Medical Partners Announces Logistics Agreement for Cardium's National Distribution of Excellagen™
-- Agreement underscores Smith Medical Partners' specialty product full-service model

http://www.theglobeandmail.com/globe-investor/news-sources/?…

[asics01]

Antwort auf Beitrag Nr.: 42.989.587 von Ahorne am 02.04.12 14:59:35

ich sag nix mehr,weiterhin glück auf.

[asics01]

Antwort auf Beitrag Nr.: 42.989.587 von Ahorne am 02.04.12 14:59:35

0,2637$,-6%

[Ahorne]

Zitat von asics01: 0,2637$,-6%

Deine smileys sind ja so Geistreich... unt tschüss...

[asics01]

Antwort auf Beitrag Nr.: 42.992.051 von Ahorne am 02.04.12 21:26:17

hallo ahorne

nimm das alles bitte nicht persönlich,das geht bestimmt nicht gegen dich.
nur dieses ganze affentheater mit dieser schon über monate gehenden kursmanipulation...ist doch nur traurig,oder schon lachhaft.
ich war auch einmal überzeugt von cxm,nur was da schon jahre lang abgeht, hat mit börse nichts mehr zu tun,das ist verarsche hoch 10.

auser es ist wirklich so,dass excellagen und generex....nicht mehr wert sind wie die 25 mio mk,dann ist das alles ok was hier abgeht.
ich werde in zukunft die weglassen.

asics

[asics01]

Antwort auf Beitrag Nr.: 42.992.105 von asics01 am 02.04.12 21:39:38

was ich noch vergessen habe,an die SANGUIANER die hier mitlesen glückwunsch an euch, so einen kursverlauf wie bei sangui hätte ich mir bei cxm auch gewünscht.

asics

[RTLOLDY]

Antwort auf Beitrag Nr.: 42.992.175 von asics01 am 02.04.12 21:53:02

....ein DANKE zurück

LG

LDY

[asics01]

Antwort auf Beitrag Nr.: 42.992.273 von RTLOLDY am 02.04.12 22:18:24

hallo rtloldy

mal eine frage sangui und cxm sind ja im gleichen segment tätig,und haben zeitgleich mit der vermarktung ihrer produkte (granulox u. excellagen)begonnen,was ist denn besser????? kann man doch miteinander vergleichen

asics

[RTLOLDY]

Antwort auf Beitrag Nr.: 42.992.323 von asics01 am 02.04.12 22:31:29

So auf die Schnelle...... Hmmmm....

Excellagen wirkt auf Collagenbasis.
Was aber die Ursache aller chronischen Wunden ist, ist die schlechte Sauerstoffversorgung der Wunde, besonders am Wundboden.
Und hier setzt das Hämoglobinspray an. Es bringt Sauerstoff dort hin wo er gebraucht wird. Dort wirkt es bildlich wie eine Mikrolunge und die Wunde heilt.
Die meisten Wundauflagen töten lediglich Keime ab, aber bekämpfen nicht die Ursache von chronischen Wunden ---> Sauerstoff fehlt !!!

Außerdem ist das Granulox ein medizinisches Produkt und ist
hiermit frei verkäuflich und kann von jeder Fachkraft angewandt werden.
Excellagen ist ein Arzneimittel und somit nicht rezeptfrei.

So mal im Groben.....

Ohne jetzt eine Kaufempfehlung aus zu sprechen, Sangui hat auf dem Markt ein
Alleinstellungsmerkmal und eine extrem hohe Heilungsrate und ist somit im Vorteil.

[asics01]

Antwort auf Beitrag Nr.: 42.992.360 von RTLOLDY am 02.04.12 22:42:55

danke für die info

und der kurs von sangui wird in d gemacht,und der von cxm bei den amis


asics

[RTLOLDY]

Antwort auf Beitrag Nr.: 42.992.398 von asics01 am 02.04.12 22:53:12

Gern geschehen......

Stimmt....... Sangui ist zwar als eine amerikanische Inc.
als Heimatbörse gelistet, aber der Kurs und der Handel
wird überwiegend an der Börse Hamburg gemacht.
Das mit der Notierung in den USA hat historische Gründe
und nach meiner Meinung schon längst bereinigungs-bedürftig.
Also Heimatbörse in BRD

LDY

[asics01]

ca. 26000000 neue aktien,und dadurch mal endlich eine mk von 32 mio.
(ahorne,diesmal keine smilies)

asics

[asics01]

sie haben schon wieder 1 mille mk weggedrückt (-5 %)mal schauen wie lange sie brauchen um wieder bei 25000000 $ mk zu stehen????


asics

[asics01]

Antwort auf Beitrag Nr.: 42.996.368 von asics01 am 03.04.12 17:37:09

mal was zum schmunzeln

04.05.2010, 10:27



Endingen (aktiencheck.de AG) - Die Experten von "Global Biotech Investing" empfehlen, bei der Cardium Therapeutices-Aktie (ISIN DE0006632003/ WKN 663200) einen Fuß in die Tür zu stellen.

Die Kollegen von Dawson James würden für den Titel aktuell ein Target von 1,50 USD ausflaggen, was die Aktie zu einem echtem echten Hot Stock mache. Bei der Gesellschaft stünden nämlich demnächst einige Trigger an: Kurzfristig dürfte insbesondere der FDA-Entscheid für das Wundheilmedikament Excellagen für Furore auf dem Parkett sorgen, während für das kommende Jahr die Fortführung der Phase III-Testreihen für das Präparat Excellerate geplant sei.

Sollten die beiden Wirkstoffe zur Behandlung von offenen Beinen bei Diabetikern die Zulassung erhalten, erwarte sie ein gigantischer Markt. Allein in den USA seien aktuell rund 24 Mio. Menschen an Diabetes erkrankt. Davon würden zwischen 5 und 10% an offenen Beinen leiden.

Erst 2007 habe Kinetic Concepts mit VAC das erste ernst zu nehmende Wundheilpräparat auf den Markt eingeführt und damit sofort Umsätze von über 1 Mrd. USD erzielt. In der Cardium Therapeutices-Story sei somit reichlich Fantasie enthalten.

Die Experten von "Global Biotech Investing" empfehlen deshalb, bei der Aktie von Cardium Therapeutics unbedingt einen Fuß in die Tür zu stellen. (Ausgabe 09 vom 03.05.2010) (03.05.2010/ac/a/a)

Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.

zuzlassung ist seit einem halben jahr da,mit der vermarktung wurde begonnen,generex in ph 3

kurs aktuell 0,2661$ = 0,19974€
das sind die fakten,und nicht das was manche puscher immer von sich geben.

asics

[asics01]

Antwort auf Beitrag Nr.: 43.003.375 von asics01 am 04.04.12 19:45:12

also all in???? ziel 1,50€, und dann in rente

[asics01]

als nächstes wollen sie das auf den markt bringen,dann fallen aber die 1,50€ locker

und Cardium Pläne zu zwei zusätzliche Nutra-Apps Produkte vorstellen - Neo-Chill ™ für Entspannung und zu helfen, Stress abzubauen und Neo-Sleep ™ zu helfen, fördern einen erholsamen Schlaf.

[Ahorne]

Es geht voran:

http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-irh…

Cardium Presents First Quarter 2012 Financial Results and Recent Developments

Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion

Cardium Reports New Catheter-Based Methods Significantly Boost Cardiac Gene Delivery In Late-Breaking Presentation at 2012 American Society of Gene & Cell Therapy Meeting

Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences

[Zukertort]

Antwort auf Beitrag Nr.: 43.191.570 von Ahorne am 21.05.12 14:01:53

Hey !

Wer ist noch dabei ? Geht hier noch was ?

MFG
Chali